CN101346463A - Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer - Google Patents
Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer Download PDFInfo
- Publication number
- CN101346463A CN101346463A CNA2006800487393A CN200680048739A CN101346463A CN 101346463 A CN101346463 A CN 101346463A CN A2006800487393 A CNA2006800487393 A CN A2006800487393A CN 200680048739 A CN200680048739 A CN 200680048739A CN 101346463 A CN101346463 A CN 101346463A
- Authority
- CN
- China
- Prior art keywords
- lymphocyte
- day
- tumour
- reactive
- lymphocytes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000001744 T-lymphocyte Anatomy 0.000 title claims abstract description 239
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 170
- 238000000034 method Methods 0.000 title claims abstract description 121
- 201000011510 cancer Diseases 0.000 title claims abstract description 20
- 238000009169 immunotherapy Methods 0.000 title description 7
- 239000000427 antigen Substances 0.000 claims abstract description 69
- 108091007433 antigens Proteins 0.000 claims abstract description 69
- 102000036639 antigens Human genes 0.000 claims abstract description 69
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims abstract description 44
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims abstract description 44
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims abstract description 44
- 238000011161 development Methods 0.000 claims abstract description 38
- 239000003550 marker Substances 0.000 claims abstract description 21
- 230000012010 growth Effects 0.000 claims abstract description 6
- 239000002458 cell surface marker Substances 0.000 claims abstract description 5
- 108040006849 interleukin-2 receptor activity proteins Proteins 0.000 claims abstract description 3
- 239000000463 material Substances 0.000 claims description 128
- 230000000527 lymphocytic effect Effects 0.000 claims description 77
- 230000000694 effects Effects 0.000 claims description 64
- 108010002350 Interleukin-2 Proteins 0.000 claims description 53
- 102000000588 Interleukin-2 Human genes 0.000 claims description 53
- 239000000556 agonist Substances 0.000 claims description 47
- 108010074328 Interferon-gamma Proteins 0.000 claims description 29
- 108010065805 Interleukin-12 Proteins 0.000 claims description 28
- 102000013462 Interleukin-12 Human genes 0.000 claims description 28
- 102100037850 Interferon gamma Human genes 0.000 claims description 27
- 238000012360 testing method Methods 0.000 claims description 23
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 22
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 21
- 238000011282 treatment Methods 0.000 claims description 21
- 210000002443 helper t lymphocyte Anatomy 0.000 claims description 20
- 102000003812 Interleukin-15 Human genes 0.000 claims description 17
- 108090000172 Interleukin-15 Proteins 0.000 claims description 17
- 108010002586 Interleukin-7 Proteins 0.000 claims description 16
- 102000000704 Interleukin-7 Human genes 0.000 claims description 16
- 108040003610 interleukin-12 receptor activity proteins Proteins 0.000 claims description 16
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 16
- 102000004388 Interleukin-4 Human genes 0.000 claims description 15
- 108090000978 Interleukin-4 Proteins 0.000 claims description 15
- 102100025137 Early activation antigen CD69 Human genes 0.000 claims description 12
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 claims description 12
- 108010002616 Interleukin-5 Proteins 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 11
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 11
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 11
- 102000003814 Interleukin-10 Human genes 0.000 claims description 10
- 108090000174 Interleukin-10 Proteins 0.000 claims description 10
- 102000004169 proteins and genes Human genes 0.000 claims description 10
- 108090000623 proteins and genes Proteins 0.000 claims description 10
- 102000001617 Interferon Receptors Human genes 0.000 claims description 9
- 108010054267 Interferon Receptors Proteins 0.000 claims description 9
- 210000005259 peripheral blood Anatomy 0.000 claims description 9
- 239000011886 peripheral blood Substances 0.000 claims description 9
- 229920001184 polypeptide Polymers 0.000 claims description 9
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 9
- 210000003719 b-lymphocyte Anatomy 0.000 claims description 7
- 210000001072 colon Anatomy 0.000 claims description 7
- 230000008859 change Effects 0.000 claims description 6
- 239000012980 RPMI-1640 medium Substances 0.000 claims description 5
- -1 for example AIMV Substances 0.000 claims description 5
- 239000008194 pharmaceutical composition Substances 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 239000012679 serum free medium Substances 0.000 claims description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 3
- 210000003484 anatomy Anatomy 0.000 claims description 3
- 239000007758 minimum essential medium Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 210000000813 small intestine Anatomy 0.000 claims description 3
- 201000009030 Carcinoma Diseases 0.000 claims description 2
- 108010050904 Interferons Proteins 0.000 claims description 2
- 102000014150 Interferons Human genes 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 2
- 206010039491 Sarcoma Diseases 0.000 claims description 2
- 206010043276 Teratoma Diseases 0.000 claims description 2
- 230000030741 antigen processing and presentation Effects 0.000 claims description 2
- 201000000053 blastoma Diseases 0.000 claims description 2
- 210000000988 bone and bone Anatomy 0.000 claims description 2
- 210000000481 breast Anatomy 0.000 claims description 2
- 201000008184 embryoma Diseases 0.000 claims description 2
- 208000010932 epithelial neoplasm Diseases 0.000 claims description 2
- 210000000981 epithelium Anatomy 0.000 claims description 2
- 229940079322 interferon Drugs 0.000 claims description 2
- 238000001361 intraarterial administration Methods 0.000 claims description 2
- 238000007912 intraperitoneal administration Methods 0.000 claims description 2
- 210000003205 muscle Anatomy 0.000 claims description 2
- 210000003739 neck Anatomy 0.000 claims description 2
- 210000000496 pancreas Anatomy 0.000 claims description 2
- 210000002307 prostate Anatomy 0.000 claims description 2
- 210000002435 tendon Anatomy 0.000 claims description 2
- 210000003932 urinary bladder Anatomy 0.000 claims description 2
- 210000003905 vulva Anatomy 0.000 claims description 2
- 108010032774 Interleukin-2 Receptor alpha Subunit Proteins 0.000 claims 1
- 102000007351 Interleukin-2 Receptor alpha Subunit Human genes 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 claims 1
- 210000004698 lymphocyte Anatomy 0.000 abstract description 66
- 230000004913 activation Effects 0.000 abstract description 31
- 239000000126 substance Substances 0.000 abstract description 9
- 230000004083 survival effect Effects 0.000 abstract description 7
- 230000004936 stimulating effect Effects 0.000 abstract description 6
- 230000001737 promoting effect Effects 0.000 abstract description 4
- 230000001105 regulatory effect Effects 0.000 abstract description 4
- 230000003213 activating effect Effects 0.000 abstract description 3
- 108010038453 Interleukin-2 Receptors Proteins 0.000 abstract description 2
- 102000010789 Interleukin-2 Receptors Human genes 0.000 abstract description 2
- 230000001270 agonistic effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 72
- 230000003321 amplification Effects 0.000 description 54
- 238000003199 nucleic acid amplification method Methods 0.000 description 54
- 210000005005 sentinel lymph node Anatomy 0.000 description 48
- 238000001994 activation Methods 0.000 description 31
- 238000001802 infusion Methods 0.000 description 26
- 229940117681 interleukin-12 Drugs 0.000 description 18
- 206010027457 Metastases to liver Diseases 0.000 description 15
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 11
- 238000004113 cell culture Methods 0.000 description 10
- 206010003445 Ascites Diseases 0.000 description 9
- 206010009944 Colon cancer Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 102000004127 Cytokines Human genes 0.000 description 9
- 108090000695 Cytokines Proteins 0.000 description 9
- 201000010989 colorectal carcinoma Diseases 0.000 description 9
- 210000004185 liver Anatomy 0.000 description 9
- 210000004881 tumor cell Anatomy 0.000 description 9
- 238000011160 research Methods 0.000 description 8
- 210000000447 Th1 cell Anatomy 0.000 description 7
- 239000003446 ligand Substances 0.000 description 7
- 210000001165 lymph node Anatomy 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000001356 surgical procedure Methods 0.000 description 7
- 238000000684 flow cytometry Methods 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000000822 natural killer cell Anatomy 0.000 description 6
- 150000001413 amino acids Chemical class 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000002512 chemotherapy Methods 0.000 description 5
- 238000002591 computed tomography Methods 0.000 description 5
- 230000036541 health Effects 0.000 description 5
- 238000000338 in vitro Methods 0.000 description 5
- 230000008595 infiltration Effects 0.000 description 5
- 238000001764 infiltration Methods 0.000 description 5
- 238000012544 monitoring process Methods 0.000 description 5
- 239000002516 radical scavenger Substances 0.000 description 5
- 239000007858 starting material Substances 0.000 description 5
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 4
- 102000008100 Human Serum Albumin Human genes 0.000 description 4
- 108091006905 Human Serum Albumin Proteins 0.000 description 4
- 102000000743 Interleukin-5 Human genes 0.000 description 4
- 102000040945 Transcription factor Human genes 0.000 description 4
- 108091023040 Transcription factor Proteins 0.000 description 4
- 230000008485 antagonism Effects 0.000 description 4
- 230000000890 antigenic effect Effects 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 230000012202 endocytosis Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 230000004927 fusion Effects 0.000 description 4
- 230000001900 immune effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 150000003384 small molecules Chemical class 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 101001018097 Homo sapiens L-selectin Proteins 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102100032700 Keratin, type I cytoskeletal 20 Human genes 0.000 description 3
- 108010066370 Keratin-20 Proteins 0.000 description 3
- 102100033467 L-selectin Human genes 0.000 description 3
- SJEYSFABYSGQBG-UHFFFAOYSA-M Patent blue Chemical compound [Na+].C1=CC(N(CC)CC)=CC=C1C(C=1C(=CC(=CC=1)S([O-])(=O)=O)S([O-])(=O)=O)=C1C=CC(=[N+](CC)CC)C=C1 SJEYSFABYSGQBG-UHFFFAOYSA-M 0.000 description 3
- 108010004729 Phycoerythrin Proteins 0.000 description 3
- 206010070834 Sensitisation Diseases 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 210000004241 Th2 cell Anatomy 0.000 description 3
- 239000003636 conditioned culture medium Substances 0.000 description 3
- 230000008034 disappearance Effects 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005210 lymphoid organ Anatomy 0.000 description 3
- 210000000664 rectum Anatomy 0.000 description 3
- 230000008313 sensitization Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 210000001599 sigmoid colon Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 241000252983 Caecum Species 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 206010011968 Decreased immune responsiveness Diseases 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 206010062016 Immunosuppression Diseases 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 230000033289 adaptive immune response Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000004534 cecum Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 210000000713 mesentery Anatomy 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- YNPNZTXNASCQKK-UHFFFAOYSA-N phenanthrene Chemical compound C1=CC=C2C3=CC=CC=C3C=CC2=C1 YNPNZTXNASCQKK-UHFFFAOYSA-N 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 239000000700 radioactive tracer Substances 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 229940104230 thymidine Drugs 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 241001227713 Chiron Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 238000012752 Hepatectomy Methods 0.000 description 1
- 101001002709 Homo sapiens Interleukin-4 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 206010027458 Metastases to lung Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000003788 Neoplasm Micrometastasis Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010034650 Peritoneal adhesions Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 206010037423 Pulmonary oedema Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 102000013275 Somatomedins Human genes 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 108091005735 TGF-beta receptors Proteins 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 description 1
- YZCKVEUIGOORGS-NJFSPNSNSA-N Tritium Chemical compound [3H] YZCKVEUIGOORGS-NJFSPNSNSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 108700025316 aldesleukin Proteins 0.000 description 1
- 108010004469 allophycocyanin Proteins 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 210000001815 ascending colon Anatomy 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 244000240602 cacao Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012321 colectomy Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 210000001731 descending colon Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- 238000007489 histopathology method Methods 0.000 description 1
- 102000055229 human IL4 Human genes 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100602 interleukin-5 Drugs 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N iron(II,III) oxide Inorganic materials O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 229920006008 lipopolysaccharide Polymers 0.000 description 1
- 230000000715 lymphocytopoietic effect Effects 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000004987 nonapoptotic effect Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- KWVYZVYHZCFYIY-UHFFFAOYSA-N phyllochlorin Chemical compound N1C(C=C2C(C(CCC(=O)OC)C(=N2)C(C)=C2NC(=C3)C(C)=C2)C)=C(C)C(C=C)=C1C=C1C(C)=C(CC)C3=N1 KWVYZVYHZCFYIY-UHFFFAOYSA-N 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229940087463 proleukin Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000005333 pulmonary edema Diseases 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000003507 refrigerant Substances 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229910052722 tritium Inorganic materials 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Images
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention discloses an improved method for expansion and activation of tumour-reactive lymphocytes, in particular CD4+ helper and/or CD8+ T-lymphocytes, which may be used for treating and/or preventing cancer. The method provides high numbers of tumour-reactive T-lymphocytes within a short time span and the possibility of directing development of tumour-reactive CD4+ helper and/or CD8+ T-lymphocytes towards specific subpopulations. The method comprises a first phase of stimulating tumour-reactive CD4+ T helper and/or CD8+ T-lymphocytes with tumour-derived antigen together with at least one substance having agonistic activity towards the IL-2 receptor to promote survival of tumour-reactive CD4+ T helper and/or CD8+ T-lymphocytes; and a second phase of activating and promoting growth of tumour-reactive CD4+ T helper and/or CD8+ T-lymphocytes, wherein the second phase is initiated when the CD25 cell surface marker (or IL-2R marker) is down-regulated on CD4+ T helper and/or CD8+ T-lymphocytes.
Description
Technical field
The present invention relates to be used for tumour-reactive lymphocyte particularly CD4+ helper and/or lymphocytic amplification of CD8+T-and activated improvement method.The T-lymphocyte is not CD4+CD25
+ HiLymphocyte, that is, the present invention does not comprise adjusting T-lymphocyte.Lymphocyte can be used for treating and/or preventing cancer.
Background technology
According to immunologic surveillance hypothesis, immunity system continues sensitization with antagonism development knurl, and wherein experimental evidence is effectively supported this notion.Identify that the specificity tumor antigen provides the new possibility that is used for the knurl immunotherapy, and many immunotherapy methods have changed clinical trial at present over to.Wherein, as if the lymphocytic adoptive transfer of tumor antigen specificity is promising especially.Up to now, these effort usually based on the monocyte that derives from peripheral blood or with the knurl lymphocyte infiltration (TIL) of fresh knurl sample separation.In test recently, reported with self the shifting of TIL of amplification and treated the malignant melanoma patient that the target response rate is up to 51%.The til cell comparatively small amt is because the permanent immunity that exists (several months) knurl to generate from increasing to suppresses their common unresponsivenesses (anergy) of mechanism.In addition, scheme is at the amplification of CD8+ cytotoxic T cell, and this cell has been incorporated into chemotherapy again and carries out in the pretreated patient, and in addition, the patient handles so that the survival of CD8+T cell to be provided with the interleukin II of high dosage.
Disclosure of the Invention
The inventor had shown before that originally the activation of T cell can be present in the high degree of specificity environment of metinel lymphoid organ such as sentinel lymph node.In other words, sentinel lymph node is considered to the main position that immunity system meets with tumor antigen.
The inventor before disclosed the general method of the tumour-reactive T-lymphocytes that derives from sentinel lymph node of being used to increase, and showed might cultivate from deriving from the lymphocyte of sentinel lymph node, to obtain the culture of tumour-reactive T-lymphocytes.By the patient who removes sentinel lymph node being given the tumour-reactive T-lymphocytes with significant quantity, tumour-reactive T-lymphocytes can be used for treating cancer.
Comprise to the successful property for the treatment of and determining by measuring following factor with the cancer of tumour-reactive T-lymphocytes, such as, for example, the amount of the tumour-reactive T-lymphocytes that after amplification step, obtains, promptly, can be used for being infused to the amount of patient's tumour-reactive T-lymphocytes, obtain the required time of tumour-reactive T-lymphocytes of significant quantity, and the concentration and the ratio of the specific subgroup of the tumour-reactive T-lymphocytes that obtains by amplification method.
Therefore, the invention discloses and be used to increase tumour-reactive CD4+ helper and/or the lymphocytic improvement method of CD8+T-, wherein the specificity culture condition is through determining and optimizing, and wherein in the whole amplification phase on the monitoring T-lymphocyte with culture in the specific marker thing, with a large amount of tumour-reactive T-lymphocytes of acquisition in the shortest possible time span.In addition, the present invention provides simultaneously and has been used to guide tumour-reactive CD4+ helper and/or the CD8+T-lymphocyte method to specific subgroup development.The T-lymphocyte is not CD4+CD25
+ HiLymphocyte, that is, the present invention does not comprise adjusting T-lymphocyte.
Express the CD4 of transcription factor FoxP3
+CD25
HiThe T lymphocyte is considered to regulate T cell (Treg).Treg has the character of regulating t helper cell and T cytotoxic cell by suppressing to activate and breed, and in addition, Treg suppresses useful for example generation and the release of IFN-γ of Th1 cytokine.Therefore, developed method provided by the invention, to promote the amplification of t helper cell and T cytotoxic T cell and to avoid the Treg cell amplification.
The most common tumour-reactive T-lymphocytes that is produced by the present invention is a CD4+ helper T-lymphocyte.A purpose of amplification method of the present invention is the natural path of simulated patient autoimmunization system in some respects, and allow the immune component of patient determine whether at first to generate CD4+ helper or CD8+T-lymphocyte to a certain extent, whether this is decided by MCHI or MCHI submission according to antigen.Under most of occasions, antigen causes generating CD4+ helper T-lymphocyte by MCHII molecule submission, yet, sometimes, generate the CD8+T-lymphocyte.If generate CD4+ helper T-lymphocyte, they are as described herein being amplified further, yet this method also can be used for the CD8+ cell that increases.The inventor has been found that the amplification method that comprises two different stepss can be used for obtaining a large amount of tumour-reactive CD4+ helper and/or CD8+T-lymphocyte especially in the short period span, and described two stages are:
I) use knurl origin antigen and at least a have at the material incentive tumour-reactive T-lymphocytes of the agonist activity of IL-2 acceptor with fs of promoting the tumour-reactive T-lymphocytes survival and
Ii) activate and promote the subordinate phase of tumour-reactive T-lymphocytes growth, wherein subordinate phase ii) the CD25 cell surface marker thing (IL-2R marker) on the T-lymphocyte down timing be activated.
This amplification method also can use separation to carry out from patient's the monocyte as the antigen-specific sexual cell.When by adopting for example IL-4 of the mature cell factor, GM_CSF and IL-3 and break up and become dendritic cell then when adding Toll sample receptor for stimulating material such as lipopolysaccharides and activate this dendritic cell, give the patient and to use monocyte.The amplification of using sophisticated activation dendritic cell can promote and improve t helper cell and T cytotoxic T cell as the antigen particular cluster.
Definition
Term " tumour-reactive T-lymphocytes " is meant to have that tumor antigen is had specificity and discerns the T-lymphocyte of the TXi Baoshouti of tumor antigen.
Term " t helper cell " is meant the T-lymphocyte that promotes adaptive immune response when being activated.
Term " Th1 cell " is meant the t helper cell that promotes cell-mediated immune responses when using cytokine such as IFN-γ to be activated.
Term " Th2 cell " is meant the t helper cell that promotes humoral immunoresponse(HI) when using cytokine such as IL-4 to be activated.
Term " CD4+ helper T-lymphocyte " is meant expresses CD4 but not the T-lymphocyte of transcription factor FoxP3.
Term " CD8+T-lymphocyte " is meant the T-lymphocyte of expressing CD8.
Term " adjusting T-lymphocyte " is meant the T-lymphocyte of the inhibition adaptive immune response of expressing transcription factor FoxP3.
Term T-lymphocytic " specificity activation " that be meant antigen-specific with the activation restrictive TXi Baoshouti mediation of MHC.Whether by contrast, term T-lymphocytic " non-specific activation " is meant total activation of all T cells, no matter be that TXi Baoshouti is specific.
Term " knurl origin antigen " comprises oncocyte, knurl homogenate (this homogenate can be passed through sex change), or knurl protein, polypeptide or peptide, as be pure, natural, the form of the protein of synthetic and/or reorganization, polypeptide or peptide.Knurl origin antigen is complete molecule, its fragment, or complete molecule and/or segmental polymer or aggregate (aggregate).The suitable polypeptide and the example of peptide be for comprising about 5 to about 30 amino acid, such as for example about 10 to 25 amino acid, and about 10 to 20 amino acid, or about 12 to 18 amino acid.If the use peptide, then the spendable final volumetric molar concentration in the culture is about 0.1 to about 5.0 μ M, for example, for example, about 0.1 to about 4.0 μ M, about 0.2 to about 3.0 μ M, about 0.3 to about 2.0 μ M, or about 0.3 to about 1.0 μ M.Knurl origin antigen can be autoantigen or heterologous antigen, that is, derive from patient to be treated or derive from other the object of suffering from cancer.In an embodiment of the present invention, used self sex change knurl extract, yet, as mentioned above, also can use the knurl origin antigen in other source in the method for the invention.
Term " fs first day " or for example " subordinate phase the 5th day " can be regarded as following implication: gather in the crops the lymphocytic same day with expression in the 0th (0) day.Be defined as wherein increasing by adding the same day that at least a material (and can be substratum and/or knurl origin antigen) that has at the agonist activity of IL-2 acceptor is activated in first day of fs.The amplification stage i) can or be activated up to gathering in the crops lymphocyte at the 0th (0) day in later second day.Be known as in full at this paper the same day by adding the subordinate phase that knurl origin antigen is activated " subordinate phase first day ".
Term " sentinel lymph node " is meant first lymphoglandula of accepting the knurl lymphatic drainage.Term " metinel lymphoglandula " is meant first lymphoglandula of accepting the metastatic tumor lymphatic drainage.
Stage i)
Fs i) purpose is to obtain to comprise a high proportion of in fact tumour-reactive CD4+ helper and/or the lymphocytic culture of CD8+T-.Fs will be considered to wherein make tumour-reactive T-lymphocytes survival and splitted " child care stage ".According to the source of T-lymphocyte (starting material of amplification in vitro method), they can experience relative exacting terms in this stage, such as, suppressed by the cancer cells excretory factor.
The starting material that are used for amplification method of the present invention can be the lymphoglandula that derives from drainage primary tumor and/or metastatic tumor, such as the lymphocytic mixture of for example outpost or metinel lymphoglandula.These can be identified at intra-operative, for example, and by injection lymphoglandula location material, such as for example around knurl or metastatic tumor and inner tracer material.Lymphoglandula location material such as for example tracer agent is transported in the Lymph capillary and accumulates in outpost/metinel inter-node, therefore discerns the lymphoglandula of drainage knurl or metastatic tumor.The inventor has shown that recently first lymphoglandula of accepting the knurl drainage is natural tumour-reactive CD4+ helper and/or the lymphocytic potential enrichment of the CD8+T-source that is used for amplification in vitro, because this lymphoglandula can contain a large amount of T-lymphocytes, it increases in experience body by sensitization and in lymphoglandula at tumor antigen.
The lymphocytic alternative source of CD4+ helper and/or CD8+T-can be a blood of suffering from the object of cancer, such as for example peripheral blood.This object can be long-term ill untreated patient, or through the patient of treatment, can obtain at knurl and by the peripheral blood T-lymphocyte of sensitization from it.Lymphocytic other the suitable source of CD4+ helper and/or CD8+T-comprises marrow, spleen tissue and knurl.
Yet in a preferred embodiment of the invention, starting material derive from outpost or metinel lymphoglandula.
The T-lymphocyte that will increase in culture can derive from object to be treated, that is, the specific tumour-reactive T-lymphocytes of the administrable that obtains can be self cell.Yet the T-lymphocyte also can derive from the source that is different from object to be treated, such as for example other suffers from the object of cancer.In the case, the tumour-reactive T-lymphocytes of recipient and amplification preferably has immune compatibility (in other words, the recipient has immunotolerance to the tumour-reactive T-lymphocytes of amplification).
And different, it will comprise multiple lymphocyte according to the difference in starting material sources, such as for example T-lymphocyte, and B-lymphocyte, antigen presenting cell, the lymphocytic mixture of T-of tumour-reactive T-lymphocytes and unactivated/anergy.For specificity promotes tumour-reactive CD4+ helper and the lymphocytic survival of CD8+T-, interpolation knurl origin antigenic substance and one or more have the material at the agonist activity of IL-2 acceptor.
As mentioned above, fs i) be activated by adding at least a material that has at the agonist activity of IL-2 acceptor.The effect of this material is by IL-2 receptor for stimulating T-lymphocyte, with the lymphocytic cell fission of promotion T-, thereby prevents necrocytosis.
The activation of the lymphocytic antigen-specific MHC of T-restriction has promoted to tumour cell identification to have the clonal expansion of specific useful T-lymphocyte populations.On the contrary, the lymphocytic non-specific activation of T will cause discerning irrelevant peptide and not have the amplification of the T lymphocyte clone of any relation with the identification of tumour cell, and therefore, the T lymphocyte of most non-specific amplification can not discerned knurl.
The objective of the invention is to promote the lymphocytic specificity of tumour-reactive CD4+ helper and CD8+T-to activate and growth.Specificity activation at some tumor antigen makes that the T-lymphocyte has therapeutic action when giving with the T-lymphocyte to the cancer patient with identical knurl type, because the T-lymphocyte is activated pointedly.
Because the relevant T lymphocyte of a spot of knurl is not had therapeutic action or is had extremely low therapeutic action at any cancer with non-specific activated T-lymphocyte.
In one embodiment of the invention, the material that has at the agonist activity of IL-2 acceptor is an agonist, and this examples of substances comprises protein, polypeptide, peptide, antibody, affine body (affibody), and fragment, fusion rotein, synthetic and/or organic molecule, such as for example small molecules, and native ligand.In preferred embodiments, this material is the native ligand of IL-2 acceptor, i.e. IL-2.
If use IL-2, it preferentially is added with low dose, in order that reduce lymphocytic apoptosis and increase the positive helper tumour-reactive T-lymphocytes of CD4 group.In specific embodiments of the present invention, the low dose of IL-2 is that about 100 international unit/milliliter culture is to about 700 international unit/milliliter culture, such as, for example about 100 international unit/milliliter culture is to about 600 international unit/milliliter culture, about 100 international unit/milliliter culture is to about 500 international unit/milliliter culture, about 100 international unit/milliliter culture is to about 400 international unit/milliliter culture, about 100 international unit/milliliter culture arrives about 200 international unit/milliliter culture to about 300 international unit/milliliter culture and about 100 international unit/milliliter culture.In specific embodiments, the addition of IL-2 is 240 international unit/milliliter culture.
Having under the situation at the material of the agonist activity of IL-2 acceptor of the non-IL-2 that uses other, the concrete dosage of these materials will make the effect that obtains be equivalent to the effect that the IL-2 by above dosage obtains.
In addition amount at least a have can be at the material of the agonist activity of IL-2 acceptor at all stage i) in be added regularly, such as, for example, in stage i) every other day, be added every three days or every three days, be used to promote fissional top condition to keep.Term " every other day; every three days or every three days " is meant at least a material that has at the agonist activity of IL-2 acceptor, at least aly have adding for the first time this at after the material of the agonist activity of IL-2 acceptor, that is, the unloading phase i) afterwards second day, the 3rd day, or beginning in the 4th day, every other day, every three days or every three days, at all stage i) in be added.
In one embodiment, at all stage i) in the material that is added regularly be the agonist of IL-2.In preferred embodiments, this material is IL-2.
Regularly, such as for example every other day, every three days or having of being added every three days also be in the above-mentioned scope at other dosage of material such as for example IL-2 of the agonist activity of IL-2 acceptor.
Fs i in amplification) other important step is to add knurl origin antigen, is the cell fission of tumour-reactive T-lymphocytes with the T-lymphocyte that promotes expression to discern the t lymphocyte receptor of tumor antigen.
The optimum time point that adds tumor antigen is according to the difference in lymphocyte source and different.When lymphocyte during from lymphoglandula such as for example sentinel lymph node or from knurl, lymphocyte can experience with tumour cell very near and the immunosuppression of tumour cell, and need to use material such as for example IL-2 material that has at the agonist activity of IL-2 acceptor to cultivate the ability of some days to promote that the T-lymphocyte is replied propagation when tumor antigen is presented.Therefore, in this case, knurl origin antigen is preferentially from fs i) be added in second day to the 5th day, such as for example at second day, the 3rd day, the 4th day, or be added in the 5th day.
If lymphocyte comes autoblood, then as fs i) knurl origin antigen is added when starting, that is, be added with the material that has at the agonist activity of IL-2 acceptor, because the T-lymphocyte does not experience the immunosuppression of above-mentioned tumour cell.Therefore, when using blood, basically when stage i) starts or at the 2 days interpolation knurl origin antigen at the most after the stage i) startup.
Knurl origin antigen, such as for example knurl homogenate, may be by being present in antigen presenting cell such as for example B-lymphocyte, dendritic cell and scavenger cell in the starting material by endocytosis and processing.Under most of occasions, knurl origin antigen will be by the fissional MCHII molecule submission that causes CD4+ helper tumour-reactive T-lymphocytes.Yet, by intersecting submission, the antigen that is ingested by endocytosis can be in causing the I class depression of CD8+T lymphocyte activator processed and submission.As mentioned above, one of purpose of amplification method is the natural path of simulated patient autoimmunization system in some aspects, and allow the immune component of patient determine whether to generate CD4+ or CD8+ lymphocyte to a certain extent, whether decide by MCHI or MCHII submission according to antigen.Under most of occasions, antigen is by causing the lymphocytopoietic MCHII molecule of CD4+ helper T-submission, yet, sometimes, generate the CD8+T-lymphocyte.
Stage ii)
Subordinate phase purpose ii) is tumour-reactive CD4+ helper and/or the CD8+T-lymphocyte that activates and increase and obtain from stage i), and obtains tumour-reactive CD4+ helper and/or the lymphocytic specific subgroup of CD8+T-by guiding them to enter desired paths.
Ii) a method of optimum time point is to be undertaken by the expression of the CD25 cell surface marker thing on the monitoring T-lymphocyte unloading phase that the inventor having been found that and determines, thereby determines that specifically the T-lymphocyte is to stimulating the responsive time again.The inventor has been found that subordinate phase ii) preferably is activated when the CD25 down-regulated expression on the T-lymphocyte.CD25 is the activation tagging thing, shows that lymphocyte accepted activation signal.If when the CD25 on the T-lymphocyte highly expresses, start subordinate phase, then mean lymphocyte received signal, necrocytosis will take place.
The downward modulation of CD25 is defined as the T-lymphocyte populations of substantial part and expresses CD25 marker seldom or do not express the CD25 marker in fact.In preferred embodiments, the downward modulation of CD25 is defined as being lower than 5% T-lymphocyte populations and expresses CD25, that is, in the culture 95% or higher T-lymphocyte do not express CD25.5% or the T-lymphocyte of lower expression CD25 be likely and regulate the CD4+T-lymphocyte that its constant height with CD25 is expressed.In addition, T-lymphocyte populations preferred expression seldom the Foxp3 marker or do not express the Foxp3 marker in fact, this marker is to regulate the lymphocytic specific marker thing of T-.In preferred embodiments, the downward modulation of Foxp3 is defined as being lower than 5% T-lymphocyte populations expression Foxp3, that is, culture interior 95% or higher T-lymphocyte are not expressed Foxp3.
Except CD25, also have other marker, their expression is relevant with monitoring, to determine to start the optimum time point of subordinate phase.
The example of these markers is early stage activation tagging thing CD69, and MCHII (it is the lymphocytic activation tagging thing of T-).Because the expression of CD69 and MCHII shows T-lymphocytic " active program " and starts, mean that then this cell can not respond other stimulation, these two markers will preferably downward modulation before starting subordinate phase.The term downward modulation can be defined as being lower than T-lymphocyte populations expression CD69 and/or the MCHII of 5-10%.
In another embodiment of the present invention, during the amplification ii) of the stage of amplification method, in culture, use anti-CD 4 antibodies from possible tumour cell, to separate t helper cell.
In another embodiment of the present invention, use such as Dynabeads with anti-CD3 and anti-CD28 antibody
Product promotes the ii) interior amplification of stage of amplification method.Dynabeads
The use of CD3/CD28 will provide the lymphocyte that has activation signal, and be used in the separation from possible tumour cell in the culture.Dynabeads
CD3/CD28 will be specifically in conjunction with the antigen of T lymphocyte amplification during stage i), and wherein these cells now can be by magnetite gathering.Because activating to be activated and to have caused cloning the T lymphocyte, initial antigen-specific increases Dynabeads
CD3/CD28 stings and goads further promotion clonal expansion into action, because stage i) is not supported the activation of non-specific T lymphocyte clone.
Although when stage definite starting point ii) will obtain the difference of preferred expression of specific marker thing and different according to lymphocyte, subordinate phase is ii) the most common from fs i) the 17th day to the 23rd day (containing the 23rd day) be activated, such as, for example at the 17th day, the 18th day, the 19th day, the 20th day, the 21st day, be activated in the 22nd day or the 23rd day.In other words, lymphocyte is expressed the most common fs i that is considered to of time point of the combination of the marker of preferred amounts and marker) the 17th day to the 23rd day.
The lymphocytic amplification of T-, that is, and stage i) and in suitable substratum, carry out ii) the most usually.Preferred serum-free medium or the autoserum of using is to avoid the pathophorous risk to the patient.The example of suitable standard medium comprises the AIMV substratum, and RPMI 1640, DMEM and MEM.Yet, also can use other substratum, comprise the suitable blend of amino acid, steroide, VITAMIN, somatomedin, cytokine and mineral substance.
During two stages of amplification, cell can be divided in some culture vessels to remain on the suitable cell density in the substratum.The lymphocytic density of T-will be preferably about 3 to about 600 ten thousand cells/ml substratum in the amplification stage.
During increasing, also may need to use fresh culture exchange substratum, it is the step that is known as the substratum conditioning.The time point of isolation medium and conditioned medium can determine that perhaps, this substratum can contain suitable indicator according to morphocytology and cell culture density (it will can not surpass about 600 ten thousand cells/ml), such as for example phenol indicator.If indicator is incorporated in the substratum, then the time point of isolation medium or conditioned medium can be based on the color of substratum and is decided.If use the phenolsulfonphthalein indicator, when the medium flavescence, the pH of its expression substratum becomes acidity, and then cell should separate or nurse one's health.The proper method that is used for conditioned medium that uses among the present invention can be every 3-9 days, such as for example exchanging 1/4 to 1/2 of substratum weekly, such as for example 1/3.
Except the actual conditions that this paper mentions, for other parameter, with using the standard conditions of lymphocytes culture medium growth, such as for example 37 ℃ temperature and 5% CO
2
As mentioned above, subordinate phase is ii) by being activated to being used for activating the above-mentioned knurl origin antigen of the lymphocytic T-lymphocyte interpolation of the negative T-of tumour-reactive CD25, to promote the clonal expansion of tumour-reactive T-lymphocytes.
In specific embodiments of the present invention, antigen presenting cell (APC) and knurl origin antigen are added in the T-lymphocyte.Antigen presenting cell (APC) comprises white corpuscle, and such as for example monocyte, scavenger cell and lymphocyte are such as for example B cell.The antigen of the form that these different cell types usually can submission be discerned by the T lymphocyte specific acceptor.From for example blood, lymph liquid, marrow, lymphoid organ tissue or tissue culture medium that patient to be treated obtains, isolate the white corpuscle preparation.In preferred embodiments, the APC cell is to comprise antigen presentation B cell and/or monocytic peripheral blood white corpuscle through irradiation.The addition of APC is that about 50 ten thousand APC/ milliliter lymphocyte cultures are to about 500 ten thousand APC/ milliliter lymphocyte cultures, arrive about 400 ten thousand APC/ milliliter lymphocyte cultures such as for example about 100 ten thousand APC/ milliliter lymphocyte cultures, about 100 ten thousand APC/ milliliter lymphocyte cultures are to about 300 ten thousand APC/ milliliter lymphocyte cultures, or about 100 ten thousand APC/ milliliter lymphocyte cultures are to about 200 ten thousand APC/ milliliter lymphocyte cultures.
Except adding knurl origin antigen to the clonal expansion of T-lymphocyte with the promotion tumour-reactive T-lymphocytes, subordinate phase ii) comprises adds the specificity component, and its effect is that the guiding tumour-reactive T-lymphocytes increases to required subgroup.
As mentioned above, the invention provides the lymphocytic method of tumour-reactive CD4+ helper T-that generates.As tumor antigen and the main II of histocompatibility complex (MCHII) when molecule combines, CD4+ helper T-lymphocyte identification and in conjunction with this tumor antigen.Activated CD4+ helper T lymphocytic emiocytosis cytokine, protein and/or peptide, other cell of their stimulating immune systems such as other lymphocyte.The modal cytokine of excretory is interleukin II (IL-2), and it is powerful T B cell growth factor.The propagation CD4+ helper T-lymphocyte that is activated can be divided into two maxicell hypotypes, Th1 and Th2 cell, and it defines according to the specific cell factor that produces.The Th1 cell generates interferon-and interleukin 12 (IL-12), and the Th2 cell generates interleukin 4, interleukin 5 and Interleukin-13.Th1 T-lymphocyte it is believed that and promotes cytotoxic T lymphocyte (Tc), NK cell, scavenger cell and monocytic activation, all these cells can attack cancer cells and resist knurl usually.
Th1 and Th2 type T-helper (CD4+) lymphocyte can be divided into memory-type cell and effect type cell.Memory-type T-helper (CD4+) lymphocyte has specificity to the antigen that they at first suffer from, and can be convened in secondary immune response, causes more rapidly and bigger replying tumor antigen.Lymphocyte survival at least 20 years are described in the mankind on evidence; Perhaps survival throughout one's life.Effect type CD4+T-lymphocyte is the active cells that produces cytokine and INF-γ.
Effective treatment for cancer, give with the tumour-reactive T-lymphocytes of Th1 type useful especially, because it is believed that, the type promote cytotoxic T lymphocyte (Tc), NK cell, scavenger cell and monocytic activation, all these cells can attack cancer cells and resist knurl usually.Promptly, in specific embodiments, the present invention relates to generate the lymphocytic method of tumour-reactive CD4+ helper T-, and in other embodiment, the lymphocytic percentage ratio of T-of the Th2 type that is generated by the inventive method is 30% or lower, such as for example 25% or lower, 20% or lower, 15% or lower, 10% or lower, 5% or lower, or 0%, that is, generate the tumour-reactive CD4+T-lymphocyte of at least 70% Th1 type, such as for example at least 75%, at least 80%, at least 85%, at least 90%, the tumour-reactive CD4+T-lymphocyte of at least 95% or 100% Th1 type.
Therefore, subordinate phase can comprise that interpolation can raise the material of the IL-12R on the T-lymphocyte.The rise of IL-12R will increase the T cell to accepting and optimizing IL-12 cytokine activated and prepare, and cause maximum STAT-4 signal conduction, and therefore make lymphocyte generate to Th1 cell and IFN-γ.
The material that can raise the IL-12R on the T-lymphocyte can be the material that has at the agonist activity of Interferon Receptors.In one embodiment of the invention, the material that has at the agonist activity of Interferon Receptors is an agonist, and this examples of substances comprises protein, polypeptide, peptide, antibody, affine body, and fragment, fusion rotein, synthetic and/or organic molecule, such as for example small molecules, and native ligand.In specific embodiments, this material is the native ligand of Interferon Receptors, i.e. Interferon, rabbit is such as interferon-' alpha '.
The material that interpolation can be raised the IL-12R on the T-lymphocyte can be determined according to the level of measuring the IL-12 in the substratum such as the optimum time point that for example has at the material of the agonist activity of Interferon Receptors.When with the stage ii) first day the level of IL-12 compare, the level of IL-12 is at least 1 times, such as for example at least 2 times, at least 3 times, at least 4 times, or at least 5 multiplication added-time, preferably adds described material.Under most of occasions, as seen the increase of this IL-12 level can start 1st day to 4th day (comprise 4th day) of subordinate phase after ii), and at the 2nd day, the 3rd day or the 4th day were as seen such as for example.
For the generation of the tumour-reactive T-lymphocytes of avoiding the Th2 type in fact, subordinate phase can comprise further that adding one or more can resist the material of the lymphocytic development of Th2 type T-.This examples of substances be can in and the material of interleukin-IL-4, IL-5, IL-10 and/or TGF-β (latter is not an interleukin-), all these four kinds of materials set up that the Th2 cytokine distributes and downward modulation Th1 cytokine generates required.
This examples of substances comprises protein, polypeptide, and peptide, solvable acceptor, antibody, affine body, and fragment, fusion rotein, synthetic and/or organic molecule, such as for example small molecules, and native ligand.In specific embodiments, thereby this material is selected from during interleukin-combines and the antibody of interleukin-, such as for example, anti-IL-4 antibody, anti-IL-5 antibody and/or anti-IL-10 antibody, and solvable acceptor (such as for example I and II type TGF-beta receptor) and TGF-β conjugated protein (such as for example LAP and/or LTBP).
Can add the material that one or more can resist the development of Th2 type T-lymphocyte in ii) first day of subordinate phase, such as for example one or more can in and the material of IL-4, IL-5, IL-10 and/or TGF-β.Yet because the antibody costliness, the interpolation of antibody also can be carried out in the later step after adding the material that can raise the IL-12R on the T-lymphocyte, such as, for example, after adding the material can raise the IL-12R on the T-lymphocyte 1 day was added in 2 days or 3 days.
In and material should with in enough and the amount of interleukin-be added, such as for example, with respect to the excessive 10-100 of the amount for the treatment of the neutral interleukin-doubly (mole).When using antibody, needing ultimate density usually is about 2 to about 4ng/ milliliter substratum.For in other type and material, should use to provide the ultimate density that provides same effect with above-mentioned effect about the described concentration of antibody.
In order to keep inhibition to the development of Th2 type T-lymphocyte, can all stage ii) in regularly, such as for example the stage ii) in every other day, one or more that add amount in addition every three days or every three days can resist the material of the lymphocytic development of Th2 type T-, such as for example one or more can in and the material of IL-4, IL-5, IL-10 and/or TGF-β.Will be understood that, term every other day, every three days or every be meant in three days at least a material that can resist the lymphocytic development of Th2 type T-all stage ii) in, after adding at least a material that can resist the lymphocytic development of Th2 type T-first the 2nd day, the 3rd day or beginning in the 4th day, every other day, be added every three days or every three days.
In addition, with regard to the stage ii) with regard to, can all stage ii) in regularly, such as for example the stage ii) in every 1-3 days, that is, at the 2nd day, the material at the agonist activity of IL-2 acceptor of having of amount was in addition added in the 3rd day or the 4th day, such as for example agonist, promote fissional top condition to keep.The dosage of the material that is added regularly is in about being used to add the material that has at the agonist activity of IL-2 acceptor in the stage i) such as in the optimum range that for example IL-2 mentioned.
For the generation of the tumour-reactive T-lymphocytes that helps the Th1 type, subordinate phase ii) can comprise adds the material that one or more promote the development of Th1 type T-lymphocyte.This examples of substances is the material that has at the agonist activity of IL-7, IL-12, IL-15 and/or IL-21 acceptor.More particularly, this material can be the agonist of IL-7, IL-12, IL-15 and/or IL-21 acceptor.The example of this agonist comprises protein, polypeptide, and peptide, antibody, affine body, and fragment, fusion rotein, synthetic and/or organic molecule, such as for example small molecules, and native ligand.In specific embodiments, this material is respectively the native ligand of IL-7, IL-12, IL-15 and/or IL-21 acceptor, such as IL-7, IL-12, IL-15 and/or IL-21.
The effect of IL-12 is the IFN-γ by stimulation IL-12R activation-inducing STAT path, thereby promotes the lymphocytic activation of Th1.The effect of IL-21 is to strengthen to the lymphocytic propagation of the T-of Th1 type, activation and development.
IL-7 and IL-15 both are by promoting the lymphocytic stable state amplification of T-, and the lymphocytic counting of T-that strengthens activated Th1 programming plays a role.
When adding one or more optimum time points that promote the development of Th1 type T-lymphocyte and be the T-lymphocyte to the modification sensitivity.If add this material when the T-lymphocyte is insensitive to modification, then this interpolation will be invalid,, can not help the lymphocytic development of Th1 type T-that is.For the material that determine to add promotes the lymphocytic development of Th1 type T-such as the optimum time point that for example has at the material of the agonist activity of IL-7, IL-12, IL-15 and/or IL-21 acceptor, can monitor the generation of the INF-γ that is undertaken by the T-lymphocyte.In preferred embodiments, one or more promote the material of the lymphocytic development of Th1 type T-, such as for example have material at the agonist activity of IL-7, IL-12, IL-15 and/or IL-21 acceptor should ii) start with subordinate phase in the level of IFN-γ the time level of IFN-γ compare when increasing and be added.
In specific embodiments, the increase of IFN-γ level can be defined as, and the level of the IFN-γ when ii) starting with subordinate phase is compared, at least 1 times of increase of IFN-γ level, and such as for example at least 2 times, at least 3 times, at least 4 times of increases.Common this increase can be with following relevant: the content IFN-γ in the substratum should be at least 100 pg/ml substratum, such as for example at least 150 pg/ml substratum, and at least 200 pg/ml substratum, or at least 250 pg/ml substratum.
When the material that determine to add promotes the development of Th1 type T-lymphocyte such as the optimum time point that for example has at the material of the agonist activity of IL-7, IL-12, IL-15 and/or IL-21 acceptor, people can further pay close attention to activation tagging thing CD25 on the CD4+T-lymphocyte and the expression of CD69, and this marker will preferentially raise.Rise can be regarded as and is, with the stage ii) the CD25 on the 1st day T-lymphocyte and the expression of CD69 compare, at least about 40% to about 60% or higher CD4+T-lymphocyte will express CD25 and CD69, show that the T-lymphocyte accepted activation signal.
Usually, add promoting the optimum time point of the material of the lymphocytic development of Th1 type T-to be in interpolation can raise the material of the IL-12R on the T-lymphocyte and can resist after the material of the lymphocytic development of Th2 type T-.More specifically, add to promote the Best Times of the material of the lymphocytic development of Th1 type T-to name a person for a particular job to be in to start subordinate phase the 5th day to the 8th day after ii), such as for example at the 5th day, the 6th day, the 7th day or the 8th day.
If added IL-7, IL-12, IL-15 and/or IL-21, then each concentration range in substratum is that about 150 international unit/milliliter substratum is to about 300 international unit/milliliter substratum, such as for example 250 international unit/milliliter substratum in these materials.When using other material different with above-mentioned concrete material, these materials should be added in the substratum with ultimate density, and the effect that this ultimate density the causes effect given with being added on IL-7, IL-12, IL-15 and/or IL-21 in the above-mentioned concrete scope is identical.
As mentioned above, method of the present invention preferentially is used to the T-lymphocyte that increases, to realize the CD4+ tumour-reactive T-lymphocytes of Th1 type.Another aspect of the present invention is by using the method for the tumour-reactive T-lymphocytes that is used to increase as herein described, obtaining than relatively large memory-type T-lymphocyte.In the treatment cancer, it is naturally important that patient to be treated accepts a large amount of effector tumour-reactive CD4+T-lymphocytes, because these cells-as mentioned above-promote cytotoxic T lymphocyte (Tc), NK cell, scavenger cell and monocytic activation, all these cells can attack cancer cells and resist knurl usually.
Yet by the memory-type tumour-reactive CD4+T-lymphocyte of while administration real mass, the patient obtains to reach the provide protection that the lifelong metastatic tumor at knurl or primary tumor recurs.
Therefore, the present invention relates to prepare the lymphocytic method of memory-type T-.Usually, when the culture of the tumour-reactive T-lymphocytes that increases according to the present invention, with the memory-type tumour-reactive T-lymphocytes that obtains about 35% to about 90%, such as for example about 40% to about 90%, about 50% to about 80%, or about 60% to about 70% memory-type tumour-reactive T-lymphocytes.The inventor has inferred that before the adding tumor antigen lymphocyte in the stage i) allows the fact that is reproduced, and the stage of amplification slowly causes forming high memory-type lymphocyte to the lymphocytic ratio of effector relatively.
As mentioned above, cell surface activation tagging thing CD25 on the T-lymphocyte and the expression of CD69 can be used for determining when the important step that starts the inventive method, such as for example when starting subordinate phase ii).Therefore, at all stage i) and the stage ii) in continuously, such as for example every other day, every three days or every three days, the expression of monitoring CD25 and CD69 was useful.
Because one of purpose of the inventive method is to obtain a large amount of specific C D4+ tumour-reactive T-lymphocytes, it can be used for being administered to the patient, can cause amplification step to stop at some time point results tumour-reactive T-lymphocytes.When the optimum time point of results tumour-reactive T-lymphocytes was a down-regulated expression as the CD25 on the T-lymphocyte, wherein downward modulation was defined as 5% or lower CD4+T-lymphocyte populations expression CD25.Also can determine the optimum time point of results based on the generation of measuring IFN-γ.Compare with initial IFN-γ generation, IFN-γ generates be at least 2 times of increases, such as for example at least 3 times of increases, and at least 4 times of increases, or at least 5 times of increases, initial IFN-γ generates common level corresponding at least 100 pik IFN-γ/milliliter substratum.
Usually, this incident will take place starting subordinate phase the 10th day to the 14th day (comprising the 14th day) after ii), that is, and usually at 10th day to 14th day (the comprise 14th day) harvested cell of startup subordinate phase after ii).
Therefore, the whole process that is used for the amplification of tumour-reactive T-lymphocytes according to the present invention is generally about 25 days to about 45 days (comprising 45 days), such as for example about 26 days to about 44 days (comprising about 44 days), about 27 days to about 43 days (comprising about 43 days), about 27 days to about 42 days (comprising about 42 days), about 27 days to about 41 days (comprising about 41 days), about 27 days to about 40 days (comprising about 40 days).
Timing under the CD25 marker, if do not gather in the crops tumour-reactive T-lymphocytes, the stage that they can experience one or more other bouts ii).If the amount of the tumour-reactive T-lymphocytes that obtains by described expression method is not considered to be administered to the patient's who suffers from cancer significant quantity, when perhaps if the patient is just accepting the chemotherapy scheme, it is useful doing like this, and wherein cocoa is thought and pushed away that to hold the lymphocytic administration of T-useful when chemotherapy finishes.In order to determine stage that whether tumour-reactive T-lymphocytes should experience one or more other bouts ii), people can pay close attention to the generation level of IFN-γ, and/or the sum of the tumour-reactive T-lymphocytes that obtains and/or the expression of CD25.If IFN-γ level is 30 pg/ml substratum or lower, such as for example 20 pg/ml substratum or lower, and/or the T cell is total unsatisfactory, when the T cell be CD25 feminine gender (promptly be lower than 5% T-lymphocyte populations express CD25) thereby and to stimulate again can start other bout when responsive stage ii).
Behind the results tumour-reactive T-lymphocytes, can common any ordinary method such as for example adopting density gradient method can carry out purifying by (Ficoll) substratum such as for example phenanthrene.Behind results and purifying tumour-reactive T-lymphocytes, can be by being chilled in the suitable refrigerant and with a tumour-reactive T-lymphocytes preservation.
Methods of treatment
The tumour-reactive T-lymphocytes that amplification method by above-mentioned improvement obtains can be used on treatment and suffers from the method for object of disease in knurl source, or be used in the method that the knurl that is used for realizing the knurl object degenerates, this method comprises the tumour-reactive T-lymphocytes of the present invention of the object that needs are arranged being given the usefulness significant quantity.
Method as herein described can be used for treating epithelium in any anatomy position, towards any solid tumor matter or the fetology source, such as for example, be used for the treatment of epithelioma, for example the cancer in breast, colon, pancreas, bladder, small intestine, prostate gland, neck, vulva, ovary; Between being used for the treatment of towards the matter knurl, the sarcoma in joint, bone, muscle and tendon for example, and some hematology knurl such as lymphomas; Be used for the treatment of embryoma, as teratoma.
The definition of the significant quantity of tumour-reactive T-lymphocytes is according to lymphocytic particular type, and memory-type T-lymphocyte is decided with the severity of lymphocytic ratio of effect type T-and disease.Yet, but be limited at least 1,000 ten thousand under administration average, such as for example at least 2,000 ten thousand, at least 3,000 ten thousand, at least 4,000 ten thousand, at least 5,000 ten thousand, at least 6,000 ten thousand, at least 7,000 ten thousand or at least 8,000 ten thousand tumour-reactive T-lymphocytes.The inventor determines to treat in the single dose upper limit of amount of the tumour-reactive T-lymphocytes of administration as yet.
In preferred embodiments, the tumour-reactive T-lymphocytes that is used for administration comprises effect type T-lymphocyte and the lymphocytic combination of memory-type T-.More specifically, the amount of memory-type tumour-reactive T-lymphocytes can be about 35% to about 90%, such as for example about 40% to about 90%, about 50% to about 80%, or about 60% to about 70%, and the lymphocytic percentage ratio of effect type T-is about 10% to about 65%, such as for example about 20% to about 50%, or about 30% to about 40%.
Tumour-reactive T-lymphocytes can be formulated as and be suitable for the patient is carried out parenterai administration, such as for example being suitable in intravenously, intra-arterial, the sheath or the pharmaceutical composition of intraperitoneal administration.
When the parenterai administration tumour-reactive T-lymphocytes, they can ooze in the medium waiting, that is, have equal tension with blood and comprising in the medium of the material that one or more prevent cell aggregation and preparing.The object lesson of suitable medium is 0.9% NaCI solution, and it comprises the human serum albumin up to 3%, such as for example up to 2% human serum albumin or up to 1% human serum albumin.For intravenous administration, the concentration range for the treatment of the tumour-reactive T-lymphocytes in the administration composition is that about 500,000 lymphocytes/milliliter substratum is to about 4,000,000 lymphocytes/milliliter substratum, arrive about 3,000,000 lymphocytes/milliliter substratum such as for example about 500,000 lymphocytes/milliliter substratum, about 500,000 lymphocytes/milliliter substratum is to about 2,000,000 lymphocytes/milliliter substratum, or about 1,000,000 lymphocytes/milliliter substratum is to about 2,000,000 lymphocytes/milliliter substratum.
The composition that comprises tumour-reactive T-lymphocytes can single dose or a plurality of dosed administration, and it can be by infusion in 1-2 hour.
According to the severity of disease, this methods of treatment can carry out once or repeat.In addition, when palindromia, can repeat this treatment.
Treatment of the present invention can be supplemented with any other relevant cancer therapy.This complementarity therapy can be before the administration lymphocyte, simultaneously or be given afterwards, and the frequency that this complementarity therapy can be generally used for this treatment is given.The suitable example of complementarity therapy is chemotherapy etc.
Test kit
The present invention relates to the test kit with in the methods of the invention in addition, and this test kit comprises and is used to cultivate the lymphocytic substratum of T-.This substratum can be any suitable serum-free medium, such as for example AIMV, RPMI 1640, DMEM or MEM.
Described test kit can comprise the material that one or more are used to stimulate, activate and guide tumour-reactive T-lymphocytes in addition.This examples of substances can be knurl origin antigen, has material at the agonist activity of IL-2 acceptor, the material of the IL-12R on the T-lymphocyte can be raised, the material of the lymphocytic development of Th2 type T-and/or the material of the lymphocytic development of promotion Th1 type T-can be resisted.
More specifically, this material can be IL-2, interferon-' alpha ', anti-IL-4 antibody, anti-IL-5 antibody, anti-IL-10 antibody, IL-7, IL-12, IL-15 and/or IL-21.
Described test kit also can comprise the pharmaceutical composition that is suitable for intravenous administration, and this pharmaceutical composition can mix before administration with the tumour-reactive T-lymphocytes group.
Described test kit also can comprise one or more syringes, and it comprises lymphoglandula location material, such as for example above-mentioned those.
Described test kit also can comprise working instructions, such as for example specification sheets of computer software form.
Description of drawings
Fig. 1 illustrates that sentinel lymph node is to be used for submission and the activated T cell reactive natural main position at tumor antigen.
Fig. 2 represents to activate the sentinel lymph node lymphocyte with tumor antigen and low dose of IL-2 at first, causes activation and the expression (last figure) of activation tagging thing CD25.The number that the termination that Phase I activates the stage is defined as expressing the CD4+T cell of CD25 reduces (figure below).When the CD4+T cell expressing CD25 that is lower than 5%, use antigenic II stimulate again the unloading phase.
Fig. 3 notification phase I and Phase activate amplification and the enrichment that causes the CD4+T helper.
Fig. 4 explanation most cells in Phase I is originally CD62L+ cell or activated CD69+CD62L+ cell.After Phase I 1, most cells is the CD62L-T cell and is made up of memory-type and effect type CD4+T helper.The CD62L-T cell is not expressed the preferred lymphoglandula molecule of going back to the nest, because they seek the inflammatory zone in the non-lymphoid organ.
It is interior from knurl (knurl lymphocyte infiltration) that Fig. 5 is illustrated in Phase I, and the primary cell that sentinel lymph node (SN) and uncorrelated lymphoglandula (LN) stimulate causes IFN-γ to generate seldom.
Fig. 6 explanation is after the amplification of stage after ii), and the dose-dependently that exists antigen dependency IFN-γ to generate increases.
Fig. 7 illustrates that amplification and activation process promote T cells with antigenic specificity clone's amplification, and this investigates explanation by the selective enrichment that TCR V β expresses.
Fig. 8 A-D is No. 5 patient's CT scan figure.Behind infusion tumour-reactive lymphocyte, the patient is positioned at overall degeneration of hepatic metastases knurl (it it is said and can not be cured by liver surgery) of two pallettes, the horizontal normalizing of CEA, and ascites disappearance and physical integrity are good, take exercise regularly.
Fig. 9 A-F is No. 10 patient's CT scan figure.Behind infusion tumour-reactive lymphocyte, patient's hepatic metastases knurl and ascites are degenerated.Its healthy state generally shows stable disease well and through instant picture photography.
Figure 10 A-H is No. 12 patient's CT scan figure.After infusion 3 months, the metastatic tumor in its liver and the lung is degenerated, and the CEA level is almost normal, is 5.9 (standard value＜4.0), and ascites disappears, and clinical manifestation health.
When being presented at the beginning (A) of amplification and stopping (B), Figure 11 is used to express the T lymphocyte that is colored the CD4+ that is used for CD25 and transcription factor FoxP3 expression through gate.Beginning (figure A), 4.8% CD4+T lymphocyte is expressed FoxP3 and high-caliber CD25, therefore is called Treg.When amplification stops, there is the Treg (figure B) of minute quantity (0.3%).
Embodiment
Embodiment 1
The amplification of tumour-reactive T-lymphocytes
Use the operation of sentinel lymph node technology to identify sentinel lymph node, in brief, the patent blue dyestuff of injection 1ml in the serous coat around the knurl (Guerbet, Paris) and carry out surface arrangement.In 5-10 minute, 1-3 mesenteric lymph nodes dyed blueness, and these sentinel lymph nodes make marks with suture and are removed (referring to Fig. 1).Non-outpost's mesenteric lymph nodes, itself and knurl away from, also identified and be removed in contrast.
Sentinel lymph node and non-sentinel lymph node are cut in half, and get 1 millimeter slab from center and periphery.Remaining lymphoglandula is sent to the histopathological examination of doing routine.Also take out a part of knurl (it comprises the sample that soaks into the edge) and be used for research purpose.
Cell cultures
Phase I, the initial activation
The sentinel lymph node material is kept on ice and uses immediately and always AIM V
Substratum (Invitrogen) is taken care of.By in the glass homogenizer of slack running fit, carrying out gentle homogenate, and after the homogenate cell washed twice in substratum is being obtained the lymphocytic single-cell suspension liquid of sentinel lymph node.The sentinel lymph node lymphocyte is placed the cell cultures flask with the concentration of 4,000,000 cells/ml, and add interleukin II (IL-2) (Proleukin
, Chiron) to the concentration of 240 international unit/milliliter substratum.
By using Ultra Turrax, prepared self knurl extract in 5 minutes 97 ℃ of sex change then in 5 volumes (w/v), 2 x PBS homogenate.Concentration is added and is self knurl extract of 1/100 in after cell cultures begins 3 to 4 days.For long-term cultivation, cell is placed 37 ℃ and 5%CO
2Cell culture incubator in, and added the IL-2/ milliliter substratum of 240 international unit in every 3-4 days.
Phase activates and amplification
After 18-22 days, the expression of the CD25 of monitoring cell culture.When the reduced number of CD25 express cell when being lower than 5%, in Phase (Fig. 2), be that self knurl extract pair cell of 1/100 stimulates again by adding concentration.For effective antigens is presented, use Fick-Pa PLUS (Amersham Biosciences, GE Healthcare) to collect self PBMC, and shine and add in the cell culture with 2500 absorbing radiation dose units.After stimulating again 3 days, the concentration of adding concentration and be the interferon-' alpha ' (Introna) of 100-500 international unit/milliliter and adding anti-IL-4 antibody to 2 μ g/ milliliter.After 5-8 days, in amplification procedure, add IL-12 (4ng/ml) inducing with the Th1 cell that promote to generate IFN-γ.
In the day before yesterday, use Fick-Pa PLUS (Amersham Biosciences, GE Healthcare) pair cell culture to carry out purifying, thereby give the viable cell in the culture for change patient's infusion.On infusion same day, cell salts solution (Natriumklorid Baxter Viaflo 9mg/ml, Baxter) in washed twice, be transferred to then in the transfering bag that contains 100-200ml salts solution and 1% human serum albumin (Baxter).Before infusion, check the existence of microorganism.In 1-2 hour, finish cell infusion under the professional medical supervision.
Immunological evaluation
Use thymidine to carry out further immunological evaluation in conjunction with proliferation test with the tritium spike.The sentinel lymph node lymphocyte of reserving aliquot is used for this purpose, by obtaining the lymphocytic single-cell suspension liquid of non-sentinel lymph node in the interim homogenate of carrying out gentleness of the glass homogenate of slack running fit, and by Fick-Pa PLUS (Amersham Biosciences, GE Healthcare) purifying peripheral blood white corpuscle.
With the cell resuspending and in the RPMI 1640 that contains 2.5% foetal calf serum (FCS) (Life technologies) (Life technologies) washed twice.At last, cell is resuspended in RPMI 1640 proliferated culture mediums that contain 10% people AB serum (Sigma), 1% penicillin-Streptomycin sulphate (Sigma) and 1% glutamine (Sigma).In 96 orifice plates with 3 * 10
5The concentration of individual cells/well is used the PBL of lymph-node cell and purifying, and uses knurl homogenate or Con A 10 μ g/ml (Sigma) with 1/100,1/10 dilution to stimulate in triplicate.Before results, passed through to add 1 μ Ci's in 18 hours
3Propagation was measured in H-thymidine/hole (Amersham) at the 5th, 6 and 7 day.Sample experience scintillation counting.
When the beginning cell cultures, in 96 orifice plates, use 3 * 10
5The concentration of individual cells/well is used the stimulation that is used to measure IFN-y excretory lymph-node cell and PBL in triplicate with 1/10 and 1/100 knurl homogenate of diluting or Con A 10 μ g/ml (Sigma).Culture supernatant in the sample of in triplicate merging is carried out ELISA (Human IFN-y Duoset, R﹠amp; DSystems) measure the secretory volume (Fig. 5) of IFN-y.When cell cultures stops, take out the sample of supernatant liquor, use ELISA (Human IFN-Duoset and Human IL-4 Duoset, R﹠amp; D Systems) measures IFN-γ and IL-4 secretion (Fig. 6 A and 6B) in triplicate.
Flow cytometry
Initial use flow cytometry to derive from sentinel lymph node, non-sentinel lymph node, PBMC's and the cell that derives from knurl carry out cell and characterize.The lymphocyte that derives from sentinel lymph node that every 2-3 week is obtained in culture sample is used for flow cytometry.The antibody of cell and anti-marker is being supplemented with 2%FCS and 0.05%NaN
3Cultivate among the PBS of (FACS damping fluid) and be used for immunocyte subgroup in 30 minutes and be used for lymphocyte activation (Fig. 3,4 and 5).Use the following marker of antagonism with fluorescein isothiocyanate (FITC) bonded antibody: CD69, HLA-DR, CD45RA, CD25, the antagonism following marker with phycoerythrin (PE) bonded antibody: CD62L, CD19, CD45RO, CD56, the following marker of antagonism with perdinin phyllochlorin (PerCP) bonded antibody: CD8, CD3, resist following marker with allophycocyanin (APC) bonded antibody: CD4, CD14, CD8.
Use Beta mark test kit (Beckman Coulter) to detect V β repertoire, with 5 * 10
5Individual cell/test tube dyes in 8 of 10 μ l different bottles, and described bottle contains the mixture of FITC, PE and double-colored FITC-PE mating type TCR V β antibody, and adds CD8PerCP and CD4APC (Fig. 7) in each test tube.
By administration tumour-reactive T-lymphocytes treatment colorectal carcinoma
Identify and take out sentinel lymph node and the metinel lymphoglandula that derives from the colorectal carcinoma patient:
Studied 16 patients that suffered from colorectal carcinoma by diagnosis, six women and ten male sex, the mean age is 62 years old.The patient is divided into Duke ' s C or D phase on anatomical pathology.Also have 5 Duke ' s B phase patients to have aggressive knurl feature, such as ulcer, blood vessel or paraneural infiltration.Yet the 7th and No. 14 the patient had before experienced the colorectal carcinoma operation, and recurred disease at present, and the hepatic metastases knurl is arranged.The approval the research of local Ethics Committee and every patient provide Informed Consent Form.
Sentinel lymph node or metinel lymphoglandula are identified in operation.Make colon knurl position displacement take place by division of peritoneal adhesions so that to knurl and mesenteric mesaraic inspection.(Guerbet Paris) carries out surface arrangement to the patent blue dyestuff of injection in the serous coat around the knurl.In 5 minutes, 1-3 mesenteric lymph nodes dyed blueness, and these three sentinel lymph nodes are indicated and are removed with suture when finishing excision.Handled in the same manner one with knurl away from non-outpost's mesenteric lymph nodes.
Sentinel lymph node and non-outpost are cut in half, and get the 1mm slab from center and periphery.Remaining lymphoglandula is sent to does customary histopathological examination.Use a slice knurl (it comprises the infiltration edge of a part) to be used for antigen prepd.
The lymphocyte that derives from lymphoglandula increases as described in embodiment 1.
The administration of tumour-reactive T-lymphocytes:
16 patients treat as self lymphocyte that increases as described in the embodiment 1 by infusion.As the infusion agent, administration the T cell of 7,470 ten thousand activated of average out to and clonal expansion.Do not observe such as have a fever, feel cold, uncomfortable, serious fluid retention, pulmonary edema or dyspneic toxic side effect.
Tracking evaluation
Tracking evaluation comprises every 3-6 month clinical examination and controls the CEA level.All III and IV phase patient carry out the CT (computer tomography) research of chest and abdomen in addition.Patient average 13 months (5-20 month) regularly looks for, and the intermediate value tracking time is 13
1/
2Individual month.In 16 patients that treat through infusion self lymphocyte, have that 8 patients are known when diagnosis a remote metastatic tumor.Four patients are owing to infusion has been accepted in known palindromia, and wherein three patients are not still recurred sign.A patient is because independent hepatic metastases knurl has been carried out operation and not recurrence after surgery.From Fig. 8 and Fig. 9 as can be known; patient's hepatic metastases knurl behind infusion tumour-reactive lymphocyte that has hepatic metastases knurl (it it is said and can not cure by liver surgery) in two pallettes is totally degenerated; and the horizontal normalizing of CEA, ascites disappearance and in excellent health and exercise regularly in addition.Other patient's hepatic metastases knurl behind infusion of suffering from the hepatic metastases knurl is degenerated and ascites disappearance (referring to Figure 10,11 and 12).Patient behind infusion 3 months, the metastatic tumor in liver and the lung is degenerated (referring to Figure 13,14,15 and 16), and the CEA level is almost normal, is 5.9 (standard value＜4.0), and ascites disappears and it shows as clinical health.
The result
16 patients that suffer from colorectal carcinoma or independent colorectum hepatic metastases knurl undergo surgery and are included in this research at the SouthStockholm General Hospital.The main position of knurl is: 3 at caecum, and 4 at the ascending colon, and 1 at descending colon, 7 sigmoid colon and 1 at rectum.Carried out 1 right side colon and partly excised, 1 left side colon partly excises, 7 sigmoid colon excisions and 1 rectum resection.Two patients are before through rectum resection and sigmoid colon excision; They experience at present because the local hepatectomy of hepatic metastases knurl.A kind of patient is two belly position recurrences and before experienced the operation of caecum knurl.In operation, determined the sentinel lymph node of two drainage metastatic tumors, one in the colon mesentery, another is in the mesentery of small intestine.Carried out having the extension excision of mesenteric mesaraic identical ileum colon regions.
In whole patients, identify individual (2.1 of the mean numbers) sentinel lymph node of 1-3 by operation injection patent blue around tumour.In the patient who carries out first colectomy, obtain average 15.8 lymphoglandula again from each sample.After these lymphoglandula are carried out histopathological examination, 5 patients are in Duke ' the s C phase, 5 patients are in Duke ' the s B phase, and all these patients are owing to the growth of tumour cell along neural and blood vessel in the pathological anatomy inspection is divided into excessive risk knurl classification.5 patients have remote metastatic tumor and be in Duke ' the s D phase when metastatic tumor excise.Two patients among them have independent hepatic metastases knurl.In addition, also the antibody analysis by FACS (fluorescence activated cell sorter) and anti-cell Keratin sulfate 20 sentinel lymph node, cytokeratin 20 is used to detect the micrometastasis purpose by the expression of colorectal carcinoma tumour.Analyze consistent by flow cytometry to the cytokeratin 20 that lymphoglandula carries out with the pathological diagnosis (not shown), except in a case, false negative sentinel lymph node (according to histopathological analysis) is outside the male in cytokeratin 20 facs analysis.
Sentinel lymph node is first lymphoglandula of knurl drainage and is first position (Dahl etc.) of nodus lymphoideus transferring rate knurl therefore, but other sentinel lymph node also is the main position that is used for immune system activation.Tumour cell, fragment, non-viable non-apoptotic cell and antigen presenting cell accumulate in the sentinel lymph node, and submission, activation and clonal expansion at the T cell of knurl take place there.The inventor has utilized the T cell mass that increases in the lymphocytic body that derives from this sentinel lymph node to be used for cell in vitro cultivation, amplification and infusion.
The lymphocyte that derives from sentinel lymph node is to be activated and the T cell mass of clonal expansion at tumor antigen, and it can be gathered in the crops in surgical procedure effectively.Opposite with the immunotherapy test that concentrates on cytotoxic T cell recently, what the inventor aimed at is to generate the external enhancing process that is used for the t helper cell clonal expansion of startup in the body.T helper cell cytotoxic T cell performance useful effect seemingly and generation memory cell are necessary.In addition, in the antigenic TXi Baoshouti transgenosis of islet cell system, the infusion of Th1 cell is found the destruction that enough is used for the β cell and the development of diabetes at target.The lymphocytic vitro culture that derives from sentinel lymph node causes the Th1 of t helper cell to activate and clonal expansion, shown in the enrichment of mastery generation that indicates Th1 cytokine IFN-γ and restrictive TCR V β repertoire.The antigen presenting cell of activated II level submission of the CD4+T helper that the knurl homogenate of T cell may be by the favourable t helper cell that is used to cause to increase of being used to increase carries out endocytosis and processing.By intersecting submission, the antigen processed and existence in causing the activated I class depression of CD8+ cytotoxic T cell that is ingested by endocytosis.Be that the inventor finds the two clonal expansion of CD4+ and CD8+T cell in some cases enjoyably.
The lymphocytic mean number that derives from sentinel lymph node when the amplification beginning is 10,740 ten thousand cells (scope is ten thousand of 360-50900,7,000 ten thousand of intermediate values).Characterize by the flow cytometry pair cell.In when beginning, the ratio of CD4+ and CD8+ is average 4.9 (scope is 0.36-10, intermediate value 5.4), shows that the CD4+T helper in the sentinel lymph node has amplification (Fig. 2 A) with CD4/CD8 in the peripheral blood than (normal range is 1.0-2.5).In addition, bone-marrow-derived lymphocyte (CD19) and NK cell (NK) cell (CD 56) are present in (not shown) in the sentinel lymph node.Described cell keeps average 36.1 days (scope is 23-58 days, intermediate value 33 days) in substratum.At least weekly by the flow cytometry cell of looking over one's shoulder.The initial cell sum reduces.B cell and NK cell almost completely disappear, and CD8+T killer cell number reduces.The culturing process of using mainly promotes the amplification of t helper cell, because the mean number of CD4/CD8 ratio is 92.5.That uses self tumor antigen stimulates the clonal expansion that causes tumour-reactive T cell again, this by research before vitro culture and the lymphocytic TXi Baoshouti V β repertoire that derives from sentinel lymph node afterwards estimate.
Before infusion, the T cell that has detected amplification is undertaken by activation and the cytokine production of measuring Th1 cytokine IFN-γ and Th2 cytokine IL-4 at the function of self tumor antigen.The lymphocyte that derives from sentinel lymph node of amplification in vitro produces the stimulation again of tumor antigen and replys, and produces IFN-γ, and does not produce or produce IL-4 seldom, and the T cell that shows amplification has effect and is that Th1 replys.
6 Duke ' s D phase patients treat in this research.2 Duke ' s D phase patients to liver with in lung and liver in the operation of metastatic tumor, show tangible disease degenerate (the 5th and No. 12 patient) respectively.Behind the infusion lymphocyte, the hepatic metastases knurl (it it is said can not by liver surgery cure) of No. 5 patient in two pallettes is overall degenerates (Fig. 3), the horizontal normalizing of CEA, and ascites is missing and performance is healthy.Metastatic tumor in No. 12 patient liver and the lung is degenerated, and CEA water is almost normal, is 5.9 (standard value＜4.0), and ascites disappears and clinical manifestation health.No. 1 patient (woman) shows the size of hepatic metastases knurl and degenerates, and the CEA level reduces at first, and ascites disappears, and in good condition when its sudden death (the 191st day), seems due to the pulmonary infarction.Two Duke ' s D phase patients show stable disease, do not have the development of metastatic tumor or the increase of CEA level.Oldest No. 7 patient (woman) shows 5 months by a definite date the stable state of an illness, but the CEA level begins to increase afterwards, and death in the time of its 83 years old.Do not carry out necrotomy.A Duke ' s C phase patient undergos surgery, but develops into metastatic tumor to liver and lung (Duke ' s D phase) soon, but after infusion and chemotherapy, the degeneration of visible lung and hepatic metastases knurl, and the slight rising of CEA level is only arranged.All patients that are in Duke ' the s C phase have the CEA level of standard, and without any the radioactivity or the clinical recurrence sign of disease.Four Duke ' s B phase patients are healthy, have the CEA level of standard and do not have the palindromia sign.No. 9 the patient is in Duke ' the s B phase, but has invasive growth knurl, shows disease relapse, and the CEA level improves (67) and hepatic metastases knurl sign.
For the trend of the T cell of studying infusion, the inventor has analyzed the T cell proliferation at the knurl extract in the peripheral blood.As mentioned above, the inventor can not prove before the infusion in arbitrary patient any t cell responses in the blood around at self tumor antigen.Yet the inventor can detect all that reach 10 months after all infusions and be investigated in patient's the peripheral blood T cell proliferation at self tumor antigen, shows the circulation tumour-reactive T cell that has clonal expansion.
The patient characteristic general introduction
Below be the form of all participants in this research, operation is carried out Duke ' s by stages:
Participant's feature:
A) this numeral is used the CD4 of FACS detection and the percentage ratio of CD8 positive cell.
Discuss
According to the knowledge that the inventor grasped, before the present invention, be not provided at the immunotherapy of using among the colorectal carcinoma patient based on outpost or metinel lymphoglandula.Therefore, the present invention attempts to use the lymphocyte from outpost or the acquisition of metinel lymphoglandula to be used for the treatment of for the first time.In this research with for example use and exist some between the IL-2 (Rosenberg) of high dosage than big-difference.The first, use the lymphocyte that derives from sentinel lymph node that carries out stimulated in vitro by self knurl homogenate and APC to cause cellullar immunologic response at the high degree of specificity of knurl.The T cell that only has a high affinity with primary tumor before the infusion can be survived.In the systemic general treatment of IL-2 to patient's intravenous administration that uses high dosage, all lymphocytes are stimulated comparably and are had reason to think that it is that knurl is specific that the lymphocyte of few part is only arranged.The inventor believes because sentinel lymph node is first draining lymph node of knurl, therefore has the lymphocytic excessive buildup of knurl specificity.The propagation and the infusion of real knurl identification T cell will produce large-scale knurl specific reaction.The second, the IL-2 scheme of high dosage causes high toxicity and severe complications, and treatment cycle is long, and the cost height.Infusion according to the inventive method did not have complication in about 1 hour, and the patient left hospital on the same day.The 3rd, method of the present invention is at the amplification of the t helper cell that derives from sentinel lymph node, and is opposite with the amplification of the cytotoxic T cell of being gathered in the crops as the knurl lymphocyte infiltration.
Originally studies show that the new isolating lymphocyte that derives from sentinel lymph node has the external complication that do not have when being infused into the patient at the multiplication capacity of self knurl homogenate and as adoptive immunotherapy.Use the lymphocyte that derives from sentinel lymph node of amplification to treat to have shown consumingly and can improve patient with colorectal carcinoma excessive risk or diffusive colorectal carcinoma, and the patient who suffers from various types of solid tumors.
Claims (84)
1. be used to increase tumour-reactive CD4+T helper and/or the lymphocytic method of CD8+T-, this method comprises:
I) use knurl origin antigen and at least a material incentive tumour-reactive CD4+T-helper and/or the fs of CD8+T-lymphocyte that has at the agonist activity of IL-2 acceptor to promote that tumour-reactive CD4+T-helper and/or CD8+T-lymphocyte are survived; With
Ii) activate and promote the subordinate phase of tumour-reactive CD4+T helper and/or CD8+T-lymphocyte growth, wherein subordinate phase ii) the CD25 cell surface marker thing (or IL-2R marker) on CD4+T helper and/or CD8+T-lymphocyte down timing be activated.
2. the process of claim 1 wherein downward modulation be defined as 5% or lower T-lymphocyte populations express CD25.
3. claim 1 or 2 method, wherein the T-lymphocyte is present in the substratum.
4. the method for claim 3, wherein substratum is a serum free medium, such as for example AIMV substratum.
5. each method, wherein fs i in the aforementioned claim) be activated by adding at least a material that has at the agonist activity of IL-2 acceptor.
6. the method for claim 5, the material that wherein has at the agonist activity of IL-2 acceptor is IL-2.
7. the method for claim 6, wherein IL-2 is to be added such as for example following low dose, about 100 international unit/milliliter substratum is to about 700 international unit/milliliter substratum, about 100 international unit/milliliter substratum is to about 600 international unit/milliliter substratum, about 100 international unit/milliliter substratum is to about 500 international unit/milliliter substratum, about 100 international unit/milliliter substratum is to about 400 international unit/milliliter substratum, about 100 international unit/milliliter substratum arrives about 200 international unit/milliliter substratum to about 300 international unit/milliliter substratum and about 100 international unit/milliliter substratum.
8. each method in the aforementioned claim, wherein in addition amount at least a has material at the agonist activity of IL-2 acceptor at all stage i) in be added regularly, such as, for example, in stage i), every other day, be added every three days or every three days.
9. the method for claim 8, the material that wherein has at the agonist activity of IL-2 acceptor is IL-2.
10. the method for claim 9, wherein the interpolation concentration of IL-2 is that about 100 international unit/milliliter substratum is to about 700 international unit/milliliter substratum, about 100 international unit/milliliter substratum is to about 600 international unit/milliliter substratum, about 100 international unit/milliliter substratum is to about 500 international unit/milliliter substratum, about 100 international unit/milliliter substratum is to about 400 international unit/milliliter substratum, about 100 international unit/milliliter substratum arrives about 200 international unit/milliliter substratum to about 300 international unit/milliliter substratum and about 100 international unit/milliliter substratum.
11. each method in the aforementioned claim, wherein knurl origin antigen is at fs i) the 2nd day to the 5th day and comprise the 5th day and be added, such as for example being added at the 2nd day, the 3rd day, the 4th day or the 5th day.
12. each method among the claim 1-10, wherein knurl origin antigen reaching 3 days at the most and be added when starting or after stage i) starts basically with stage i).
13. each method in the aforementioned claim, wherein knurl origin antigen is the knurl homogenate through sex change.
14. the method for claim 13, wherein knurl origin antigen is autoantigen.
15. each method in the aforementioned claim, wherein knurl origin antigen is protein, polypeptide or peptide.
16. each method in the aforementioned claim, wherein subordinate phase is ii) at fs i) the 17th day to the 23rd day and comprise the 23rd day and be activated, such as for example being activated at the 17th day, the 18th day, the 19th day, the 20th day, the 21st day, the 22nd day or the 23rd day.
17. each method in the aforementioned claim, wherein subordinate phase is used to activate the lymphocytic knurl origin of the negative T-of tumour-reactive CD25 antigen and is activated by adding in the T-lymphocyte.
18. the method for claim 17, wherein knurl origin antigen is autoantigen.
19. the method for claim 17 or 18, wherein knurl origin antigen is the knurl homogenate through sex change.
20. the method for claim 17 or 18, wherein knurl origin antigen is knurl protein, polypeptide or peptide.
21. each method among the claim 17-20, it comprises in addition to T-lymphocyte interpolation antigen presenting cell and knurl origin antigen.
22. the method for claim 21, wherein antigen presenting cell is to comprise antigen presentation B cell and/or monocytic peripheral blood white corpuscle through irradiation.
23. each method in the aforementioned claim, wherein subordinate phase ii) comprises at least a material that can raise the IL-12R on the T-lymphocyte of interpolation.
24. the method for claim 23, the material that wherein can raise the IL-12R on the T-lymphocyte is the material that has at the agonist activity of Interferon Receptors.
25. the method for claim 24, the material that wherein has at the agonist activity of Interferon Receptors is an Interferon, rabbit.
26. the method for claim 25, the material that wherein has at the agonist activity of Interferon Receptors is an interferon-' alpha '.
27. each method among the claim 23-26, wherein can raise the material of the IL-12R on the T-lymphocyte, such as the material that for example has at the agonist activity of Interferon Receptors, when the level of IL-12 and stage ii) the 1st day the level of IL-12 compare at least 1 times of increase, such as for example at least 2 times of increases, at least 3 times of increases, at least 4 times of increases, or at least 5 multiplications are added the added-time.
28. each method among the claim 23-27, wherein can raise the material of the IL-12R on the T-lymphocyte, such as the material that for example has at the agonist activity of Interferon Receptors, starting subordinate phase after ii) the 2nd day to the 4th day and comprising the 4th day, such as for example being added at the 2nd day, the 3rd day or the 4th day.
29. each method in the aforementioned claim, wherein subordinate phase comprises that ii) adding one or more can resist the material of the lymphocytic development of Th2 type T-.
30. the method for claim 29, wherein one or more materials that can resist the lymphocytic development of Th2 type T-be one or more can in and the material of IL-4, IL-5, IL-10 and/or TGF-β.
31. the method for claim 30, wherein one or more can in and the material of IL-4, IL-5, IL-10 and/or TGF-β be anti-IL-4 antibody, anti-IL-5 antibody and/or anti-IL-10 antibody.
32. each method among the claim 29-31, wherein one or more can resist the material of the lymphocytic development of Th2 type T-, such as for example one or more can in and the material of IL-4, IL-5, IL-10 and/or TGF-β be added in ii) the 1st day of subordinate phase.
33. each method among the claim 29-31, wherein one or more can resist the material of the lymphocytic development of Th2 type T-, such as for example one or more can in and be added in the later step of material after adding the material that can raise the IL-12R on the T-lymphocyte of IL-4, IL-5, IL-10 and/or TGF-β.
34. the method for claim 33, wherein one or more can resist the material of the lymphocytic development of Th2 type T-, such as for example one or more can in and after adding the material that can raise the IL-12R on the T-lymphocyte one day of the material of IL-4, IL-5, IL-10 and/or TGF-β be added.
35. each method in the aforementioned claim, wherein in addition one or more of amount can resist the material of the lymphocytic development of Th2 type T-, such as for example one or more can in and the material of IL-4, IL-5, IL-10 and/or TGF-β be added regularly in ii) in all stage.
36. the method for claim 35, wherein in addition one or more of amount can resist the material of the lymphocytic development of Th2 type T-, such as for example one or more can in and the material of IL-4, IL-5, IL-10 and/or TGF-β the stage ii) in every other day, be added every three days or every three days.
37. each method in the aforementioned claim, wherein in addition having at the material of the agonist activity of IL-2 acceptor of amount was added in ii) regularly in all stage.
38. the method for claim 37, wherein have at the material of the agonist activity of IL-2 acceptor the stage ii) in every other day, every three days or every three days, such as for example being added every three days.
39. the method for claim 37 or 38, the material that wherein has at the agonist activity of IL-2 acceptor is IL-2.
40. each method in the aforementioned claim, wherein subordinate phase ii) comprises the material that adds the lymphocytic development of one or more promotion Th1 type T-.
41. the method for claim 40, wherein one or more promote that the material of the lymphocytic development of Th1 type T-is the material that has at the agonist activity of IL-7, IL-12, IL-15 and/or IL-21 acceptor.
42. the method for claim 41, wherein one or more materials are selected from IL-7, IL-12, IL-15 and IL-21.
43. each method among the claim 40-42, wherein one or more promote the material of the lymphocytic development of Th1 type T-, such as the material that for example has at the agonist activity of IL-7, IL-12, IL-15 and/or IL-21 acceptor, the level of the IFN-γ when the level of IFN-γ ii) starts with subordinate phase is compared when increasing and is added.
44. the method for claim 43, wherein the increase of IFN-γ level be confirmed as be, the level of the IFN-γ when ii) starting with subordinate phase is compared, at least 1 times of increase of IFN-γ level is such as for example at least 2 times of increases, at least 3 times of increases, at least 4 times of increases.
45. each method among the claim 40-44, wherein one or more promote the material of the lymphocytic development of Th1 type T-, such as the material that for example has at the agonist activity of IL-12, IL-5 and/or IL-21 acceptor, timing is added under CD25 and/or CD69.
46. each method among the claim 40-45, wherein one or more materials that promote the lymphocytic development of Th1 type T-are that about 150 international unit/milliliter substratum arrives about 300 international unit/milliliter substratum such as each the interpolation concentration that for example has at the material of the agonist activity of IL-7, IL-12, IL-15 and/or IL-21 acceptor, such as for example 250 international unit/milliliter substratum.
47. each method among the claim 40-46, wherein one or more promote the material of the lymphocytic development of Th1 type T-, such as the material that for example has at the agonist activity of IL-12, IL-15 and/or IL-21 acceptor, starting subordinate phase after ii) the 5th day to the 8th day and comprising the 8th day, such as for example being added at the 5th day, the 6th day, the 7th day or the 8th day.
48. each method in the aforementioned claim is used to prepare CD4+ helper T-lymphocyte.
49. each method in the aforementioned claim is used to prepare effect type T-lymphocyte.
50. each method in the aforementioned claim is used to prepare memory-type T-lymphocyte.
51. each method in the aforementioned claim is used to prepare Th1 type T-lymphocyte.
52. each method in the aforementioned claim, it is included in fs i in addition) and subordinate phase monitor the expression of cell surface marker thing such as for example CD25 and/or CD69 on the T-lymphocyte during ii) continuously.
53. the method for claim 52, wherein the T-lymphocyte when subordinate phase ii) under the CD25 on the T-lymphocyte timing gathered in the crops.
54. the method for claim 53, wherein the stage that timing T-lymphocyte experiences at least one other bout under the CD25 on the T-lymphocyte ii).
55. the method for claim 53 or 54, wherein downward modulation be defined as 5% or the positive T-lymphocyte populations of lower CD4 express CD25.
56. each method in the aforementioned claim, wherein tumour-reactive T-lymphocytes is gathered in the crops starting subordinate phase after ii) the 10th day to the 14th day and comprise the 14th day.
57. the method for claim 56, wherein tumour-reactive T-lymphocytes after results through purifying.
58. each method in the aforementioned claim comprises being chilled in the ii) step of the middle tumour-reactive T-lymphocytes that obtains of subordinate phase in addition.
59. each method in the aforementioned claim, wherein the T-lymphocyte is from the lymphoglandula of drainage primary tumor and/or metastatic tumor, and perhaps the T-lymphocyte comes autoblood.
60. tumour-reactive T-lymphocytes according to each method preparation among the claim 1-59.
61. the tumour-reactive T-lymphocytes of claim 60, it is the CD4+T-lymphocyte.
62. the tumour-reactive T-lymphocytes of claim 60 or 61, it is an effect type T-lymphocyte.
63. each tumour-reactive T-lymphocytes among the claim 60-62, it is a memory-type T-lymphocyte.
64. each tumour-reactive T-lymphocytes among the claim 60-63, it is a Th1 type T-lymphocyte.
65. pharmaceutical composition, it comprises among the claim 60-64 each tumour-reactive T-lymphocytes.
66. the method for the object of knurl source disease is suffered from treatment, this method comprises the tumour-reactive T-lymphocytes of the object that needs are arranged being given among the usefulness claim 60-65 of significant quantity each.
67. realize the method that knurl is degenerated in suffering from the object of knurl, this method comprises the tumour-reactive T-lymphocytes of the object that needs are arranged being given among the usefulness claim 60-65 of significant quantity each.
68. the method for claim 66 or 67, wherein tumour-reactive T-lymphocytes passes through intravenously, intra-arterial, sheath is interior or the intraperitoneal approach is given usefulness.
69. each method among the claim 66-68 is at least 1,000 ten thousand wherein for the amount of the tumour-reactive T-lymphocytes of usefulness, such as for example at least 2,000 ten thousand, at least 3,000 ten thousand, at least 4,000 ten thousand, at least 5,000 ten thousand, at least 6,000 ten thousand, at least 7,000 ten thousand or at least 8,000 ten thousand.
70. each method among the claim 66-69, wherein giving the tumour-reactive T-lymphocytes of usefulness is effect type T-lymphocyte and the lymphocytic combination of memory-type T-.
71. the method for claim 70, wherein the lymphocytic percentage ratio of effect type T-is about 10% to about 65%, such as for example about 20% to about 50%, or about 30% to about 40%.
72. each method among the claim 66-71, wherein tumour-reactive T-lymphocytes is self.
73. each method among the claim 66-71, wherein tumour-reactive T-lymphocytes right and wrong self.
74. each method among the claim 66-73, wherein the knurl disease be selected from epithelium in any anatomy position, towards any solid tumor matter or the fetology source, such as epithelioma, for example in breast, colon, pancreas, bladder, small intestine, prostate gland, neck, vulva, entovarial cancer; Between towards the matter knurl, for example the sarcoma in joint, bone, muscle and tendon and some blood tumors are such as lymphoma; Embryoma such as teratoma.
75. be used to prepare the purposes of the medicine of the disease for the treatment of the knurl source according to the tumour-reactive T-lymphocytes of each preparation among the claim 1-59.
76. comprising, the test kit that uses in each the method, this test kit be used to cultivate the lymphocytic substratum of T-in claim 1-59 or 66-74.
77. the test kit of claim 76 comprises the material that one or more are used to stimulate, activate and guide tumour-reactive T-lymphocytes in addition.
78. the test kit of claim 76 or 77, wherein substratum is a serum free medium, such as for example AIMV, RPMI 1640, DMEM or MEM.
79. each test kit among the claim 76-78, wherein one or more are used to stimulate, activate and guide the material of tumour-reactive T-lymphocytes to be selected from: knurl origin antigen, has material at the agonist activity of IL-2 acceptor, can raise the material of the IL-12R on the T-lymphocyte, can resist the material of the lymphocytic development of Th2 type T-and the material of the lymphocytic development of promotion Th1 type T-.
80. each test kit among the claim 76-79, wherein one or more are used to stimulate, activate and guide the material of tumour-reactive T-lymphocytes to be selected from: IL-2, interferon-' alpha ', anti-IL-4 antibody, anti-IL-5 antibody, anti-IL-10 antibody, IL-7, IL-12, IL-15 and IL-21.
81. each test kit among the claim 76-80 comprises the pharmaceutical composition that is suitable for intravenous administration.
82. each test kit among the claim 76-81 comprises the syringe that comprises lymphoglandula location material in addition.
83. each test kit among the claim 76-82 comprises working instructions in addition.
84. the test kit of claim 83, wherein specification sheets is the computer software form.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US75282805P | 2005-12-21 | 2005-12-21 | |
| DKPA200501810 | 2005-12-21 | ||
| US60/752,828 | 2005-12-21 | ||
| DKPA200501810 | 2005-12-21 | ||
| PCT/EP2006/012304 WO2007071388A1 (en) | 2005-12-21 | 2006-12-20 | Improved method for expansion of tumour-reactive t-lymphocytes for immunotherapy of patients with cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101346463A true CN101346463A (en) | 2009-01-14 |
| CN101346463B CN101346463B (en) | 2012-06-13 |
Family
ID=36763835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2006800487393A Active CN101346463B (en) | 2005-12-21 | 2006-12-20 | Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer |
Country Status (5)
| Country | Link |
|---|---|
| CN (1) | CN101346463B (en) |
| AT (1) | ATE483470T1 (en) |
| BR (1) | BRPI0620187A2 (en) |
| DE (1) | DE602006017435D1 (en) |
| NZ (1) | NZ569105A (en) |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105586312A (en) * | 2016-02-29 | 2016-05-18 | 时宏珍 | Preparation method of HLA-A0201-restricting anti-MUC-1 antigen specific CTL |
| CN106103701A (en) * | 2014-01-03 | 2016-11-09 | 富禾生医股份有限公司 | The natural killer cell of transformation and composition and purposes |
| CN106754703A (en) * | 2016-12-26 | 2017-05-31 | 浙江丹晖生物科技有限公司 | A kind of til cell amplification in vitro culture medium combination and cultural method |
| CN107404881A (en) * | 2014-09-19 | 2017-11-28 | 希望之城公司 | Central memory T cell for adoptive T cell therapy |
| CN108603173A (en) * | 2015-11-02 | 2018-09-28 | 剑桥企业有限公司 | The method of T Lymphocyte expansions |
| CN109952106A (en) * | 2016-07-21 | 2019-06-28 | 伯克利之光生命科技公司 | T lymphocyte is sorted in microfluidic devices |
| CN110446928A (en) * | 2017-02-07 | 2019-11-12 | 学校法人埼玉医科大学 | For predicting the immunology biomarker of immunotherapy for cancer clinical effectiveness |
-
2006
- 2006-12-20 AT AT06841050T patent/ATE483470T1/en not_active IP Right Cessation
- 2006-12-20 DE DE602006017435T patent/DE602006017435D1/en active Active
- 2006-12-20 CN CN2006800487393A patent/CN101346463B/en active Active
- 2006-12-20 NZ NZ569105A patent/NZ569105A/en not_active IP Right Cessation
- 2006-12-20 BR BRPI0620187-3A patent/BRPI0620187A2/en not_active IP Right Cessation
Cited By (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106103701A (en) * | 2014-01-03 | 2016-11-09 | 富禾生医股份有限公司 | The natural killer cell of transformation and composition and purposes |
| CN106103701B (en) * | 2014-01-03 | 2020-04-24 | 中央研究院 | Modified natural killer cells, compositions and uses thereof |
| CN107404881A (en) * | 2014-09-19 | 2017-11-28 | 希望之城公司 | Central memory T cell for adoptive T cell therapy |
| CN108603173A (en) * | 2015-11-02 | 2018-09-28 | 剑桥企业有限公司 | The method of T Lymphocyte expansions |
| CN105586312A (en) * | 2016-02-29 | 2016-05-18 | 时宏珍 | Preparation method of HLA-A0201-restricting anti-MUC-1 antigen specific CTL |
| CN109952106A (en) * | 2016-07-21 | 2019-06-28 | 伯克利之光生命科技公司 | T lymphocyte is sorted in microfluidic devices |
| CN109952106B (en) * | 2016-07-21 | 2022-08-05 | 伯克利之光生命科技公司 | Sorting T lymphocytes in a microfluidic device |
| US11666912B2 (en) | 2016-07-21 | 2023-06-06 | Berkeley Lights, Inc. | Sorting of T lymphocytes in a microfluidic device |
| CN106754703A (en) * | 2016-12-26 | 2017-05-31 | 浙江丹晖生物科技有限公司 | A kind of til cell amplification in vitro culture medium combination and cultural method |
| CN106754703B (en) * | 2016-12-26 | 2018-03-16 | 浙江丹晖生物科技有限公司 | A kind of til cell amplification in vitro culture medium combination and cultural method |
| CN110446928A (en) * | 2017-02-07 | 2019-11-12 | 学校法人埼玉医科大学 | For predicting the immunology biomarker of immunotherapy for cancer clinical effectiveness |
Also Published As
| Publication number | Publication date |
|---|---|
| DE602006017435D1 (en) | 2010-11-18 |
| CN101346463B (en) | 2012-06-13 |
| ATE483470T1 (en) | 2010-10-15 |
| NZ569105A (en) | 2011-07-29 |
| BRPI0620187A2 (en) | 2011-11-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Abe et al. | Clinical and immunological evaluation of zoledronate-activated Vγ9γδ T-cell-based immunotherapy for patients with multiple myeloma | |
| CN101351546B (en) | Method for treating disseminated cancer | |
| AU2006328943B2 (en) | Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer | |
| Chang et al. | Phase II trial of autologous tumor vaccination, anti-CD3-activated vaccine-primed lymphocytes, and interleukin-2 in stage IV renal cell cancer | |
| Schmitz-Winnenthal et al. | A phase 1 trial extension to assess immunologic efficacy and safety of prime-boost vaccination with VXM01, an oral T cell vaccine against VEGFR2, in patients with advanced pancreatic cancer | |
| Jandus et al. | Increased numbers of circulating polyfunctional Th17 memory cells in patients with seronegative spondylarthritides | |
| CN101346463B (en) | Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer | |
| US8007785B2 (en) | Method for treating colon cancer with tumour-reactive T-lymphocytes | |
| Bonanni et al. | Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells | |
| Shimizu et al. | Postoperative dendritic cell vaccine plus activated T-cell transfer improves the survival of patients with invasive hepatocellular carcinoma | |
| Sorenson et al. | Attenuated Salmonella typhimurium with IL-2 gene reduces pulmonary metastases in murine osteosarcoma | |
| CN108697737A (en) | The composition used in immunotherapy | |
| Carlson et al. | The microenvironment of human neuroblastoma supports the activation of tumor-associated T lymphocytes | |
| Wei et al. | The CIK cells stimulated with combination of IL-2 and IL-15 provide an improved cytotoxic capacity against human lung adenocarcinoma | |
| Shigematsu et al. | Immunosuppressive effect of regulatory T lymphocytes in lung cancer, with special reference to their effects on the induction of autologous tumor‑specific cytotoxic T lymphocytes | |
| Tong et al. | Adoptive natural killer cell therapy is effective in reducing pulmonary metastasis of Ewing sarcoma | |
| Marits et al. | Detection of immune responses against urinary bladder cancer in sentinel lymph nodes | |
| CN105999249A (en) | Antigen presenting cancer vaccine having [gamma]-interferon | |
| Plain et al. | Cytokines affecting CD4+ T regulatory cells in transplant tolerance. Interleukin-4 does not maintain alloantigen specific CD4+ CD25+ Treg | |
| US8101173B2 (en) | Method for treating urinary bladder cancer | |
| Hong et al. | High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44high cells after their selective depletion | |
| Li et al. | Clinical application of cytokine-induced killer (CIK) cell therapy in colorectal cancer: Current strategies and future challenges | |
| Duran-Struuck et al. | Lack of antidonor alloantibody does not indicate lack of immune sensitization: studies of graft loss in a haploidentical hematopoietic cell transplantation swine model | |
| Rakesh et al. | TREATMENT WITH INTERLEUKIN-4 AND ALLOANTIGEN ACTIVATED TREG REVERSES ALLOGRAFT REJECTION AND INDUCES TOLERANCE | |
| JP2023063272A (en) | Modified t cells, pharmaceutical compositions, methods of making same and use methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: DAIFEILA FALUN CO., LTD. Free format text: FORMER OWNER: SENTOCLONE AB Effective date: 20110413 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20110413 Address after: Stockholm Applicant after: Day Ferla Fallon Co. Address before: Stockholm Applicant before: Sentoclone AB |
|
| ASS | Succession or assignment of patent right |
Owner name: JIANGSU SINORDA BIOLOGICAL PHARMACEUTICAL TECHNOLO Free format text: FORMER OWNER: SENTOCLONE AB Effective date: 20111222 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; TO: 215400 SUZHOU, JIANGSU PROVINCE |
|
| TA01 | Transfer of patent application right |
Effective date of registration: 20111222 Address after: 215400 No. six West Beijing Road, Jiangsu, Taicang Applicant after: Jiangsu SentoClone Co., Ltd. Address before: Stockholm Applicant before: Sentoclone AB |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20090114 Assignee: Guizhou Ruisheng Connaught Biological Medicine Co Ltd Assignor: Jiangsu SentoClone Co., Ltd. Contract record no.: 2014520000007 Denomination of invention: Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer Granted publication date: 20120613 License type: Exclusive License Record date: 20140327 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| EC01 | Cancellation of recordation of patent licensing contract |
Assignee: Guizhou Ruisheng Connaught Biological Medicine Co Ltd Assignor: Jiangsu SentoClone Co., Ltd. Contract record no.: 2014520000007 Date of cancellation: 20161102 |
|
| LICC | Enforcement, change and cancellation of record of contracts on the licence for exploitation of a patent or utility model | ||
| PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Improved method for expansion of tumour-reactive T-lymphocytes for immunotherapy of patients with cancer Effective date of registration: 20161116 Granted publication date: 20120613 Pledgee: Bank of Guiyang Limited by Share Ltd high tech branch Pledgor: Jiangsu SentoClone Co., Ltd. Registration number: 2016990000990 |
|
| PLDC | Enforcement, change and cancellation of contracts on pledge of patent right or utility model | ||
| PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20190514 Granted publication date: 20120613 Pledgee: Bank of Guiyang Limited by Share Ltd high tech branch Pledgor: Jiangsu SentoClone Co., Ltd. Registration number: 2016990000990 |
|
| PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20190619 Address after: Room 1601-1602, 16th floor, 459 Qige Road, Hangzhou Economic and Technological Development Zone, Zhejiang Province, 311080 Patentee after: Hangzhou Norda Pharmaceutical Co., Ltd. Address before: 215400 No. 6 Beijing West Road, Taicang City, Jiangsu Province Patentee before: Jiangsu SentoClone Co., Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201117 Address after: Room No.1, 2, 3, 4 [building] (3) 1 [unit] 13 [floor] 3 [building] of West China (Guiyang) high tech industry R & D and production base, Guiyang National High tech Industrial Development Zone, Guiyang City, Guizhou Province Patentee after: Guizhou Shengnuo Biotechnology Co., Ltd Address before: Room 1601-1602, 16th floor, 459 Qige Road, Hangzhou Economic and Technological Development Zone, Zhejiang Province, 311080 Patentee before: Hangzhou Norda Pharmaceutical Co.,Ltd. |
|
| TR01 | Transfer of patent right |